Clincal trials portal | Clinical trials | R&D

<!DOCTYPE html>     <html class="no-js" lang="en">  <head> <link rel="preconnect" href="https://cdn.consentmanager.net"> <script type="text/javascript" data-cmp-ab="1">window.cmp_customlanguages = [{ "l": "DE-AT", "i": "at", "r": 0, "t": "DE" }, { "l": "EN-IE", "i": "ie", "r": 0, "t": "EN" }, { "l": "EN-UK", "i": "gb", "r": 0, "t": "EN" }, { "l": "NL-BE", "i": "be", "r": 0, "t": "NL" }, { "l": "FR-BE", "i": "be", "r": 0, "t": "FR" }, { "l": "DE-CH", "i": "ch", "r": 0, "t": "DE" }, { "l": "FR-CH", "i": "ch", "r": 0, "t": "FR" }];</script> <script type="text/javascript" data-cmp-ab="1" src="https://cdn.consentmanager.net/delivery/autoblocking/55fcca1161915.js" data-cmp-host="a.delivery.consentmanager.net" data-cmp-cdn="cdn.consentmanager.net" data-cmp-codesrc="1"></script>  <script> var _mtm = window._mtm = window._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); (function() { var d=document, g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='https://cdn.matomo.cloud/grunenthal.matomo.cloud/container_pZXYDyFk.js'; s.parentNode.insertBefore(g,s); })(); </script>  <script type="application/ld+json"> { "@context":"https://schema.org", "@graph":[ { "@type":"WebSite", "@id":"https://www.grunenthal.com/#website", "url":"https://www.grunenthal.com/", "name":"www.grunenthal.com" }, { "@type":"WebPage", "@id":"https://www.grunenthal.com/en/science/clinical-trials/data-clinical-trials", "url":"https://www.grunenthal.com/en/science/clinical-trials/data-clinical-trials", "inLanguage":"en", "name":"Clincal trials portal | Clinical trials | R&D | Grünenthal Group.", "description":"As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available.", "isPartOf":{ "@id":"https://www.grunenthal.com/#website" } } ] } </script> <title>Clincal trials portal | Clinical trials | R&D | Grünenthal Group.</title> <link href="https://www.grunenthal.com/-/media/projects/shared/logos/grt/grunenthal-altes-logo-footer.svg?rev=ba8e8107aa93419bae6b36df21521a7f" rel="shortcut icon" /> <meta property="og:description" content="As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available." /><meta property="og:site_name" content="/clinicaltrials_overview" /><meta property="og:image" content="https://www.grunenthal.com/-/media/projects/shared/logos/grt/logo-grunenthal-1200x627.jpg?rev=34caa2a70fde4e6385c01646477b356b" /><meta property="og:title" content="Overview interventional clinical trials in patients Grünenthal Group" /><meta property="og:url" content="https://www.grunenthal.com/en/science/clinical-trials/data-clinical-trials" /> <meta name="description" content="As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available." /><meta name="keywords" content="Grünenthal Commitments, clinical trials, trial participants, Grünenthal sponsored clinical trials, disclosing clinical trial information, Tapentadol, Burprenorphine, Neridronic Acid, Lidocaine, Levonorgestrol, Ethynilestradiol, Faxeladol, Dienogest, Duloxetine, Clotiazepam, Cebranopadol, Chlormadinone Acetate, Axomadol, HP5303/04, HP5303/05, KF5303/01, GRT-PK-07, HP6005/10, KF6005/01, KF6005/02, KF6005/03, KF6005/04, KF6005/06, KF6005/07, KF6005/08, KF6005/09, HP8822-01, HP8810-02, HP8824-01, HP8820-01, HP8811-01, HP8825-02, HP8825-01, HP9906/06, HP9906/07, KF9906/02, KF9906/03, KF6010-02, KF7019-01, HP7020-02, HP7030-01, HP7030-03, HP8001-01; DCLF/TRMD-GRNN-01, KF8001-01, HP8002-01, HP8013-01; PRG-02-GRU/PK-PVR-01, HP8814-01, HP8814-02, KF10004/03, KF7013-01, KF7013-03, HP5503-88, HP5503-93, KF5503/12, KF5503/15, KF5503/35, KF5503/37, KF5503/42, KF5503/44, KF5503/52, KF5503/53, KF5503/58, KF5503/60, KF5503/62, KF5503/65, KF5503-66, KF5503/68, KF5503-73, KF5503-75, FO-PK 401, TRA-RSA-2, WIS-AL-TRA86-04-95, KF10004/08, HP5303/10, HP5303/11, HP5303/12, HP5303/13, KF6010/01, HP6015-01, KF7021-04, HP7030-02, KF7013-02, KF7013-04, KF5503/16, KF5503/43, KF5503/45, KF5503-72, HP7014-01, HP7014-02, HP8010-01; ESTNMG-04-GRU, HP8012-01" /> <meta property="twitter:title" content="Clinical trials portal" /><meta property="twitter:card" content="summary_large_image" /> <meta name="viewport" content="width=device-width, initial-scale=1"/> <link rel='canonical' href='https://www.grunenthal.com/en/science/clinical-trials/data-clinical-trials' /> <link href="/-/media/base-themes/core-libraries/styles/optimized-min.css?rev=4b4a1e4409414b318c37ea4f472b86c7&t=20240826T134041Z&hash=17A5B1A83032D6C7428773899D3FA313" rel="stylesheet" /><link href="/-/media/base-themes/main-theme/styles/optimized-min.css?rev=bdcd08291c484b34bbf28e7652c6a310&t=20250222T204337Z&hash=DEAD7FF5686069C454FE61435625ED33" rel="stylesheet" /><link href="/-/media/themes/grunenthal/groupsite/toolkit/styles/optimized-min.css?rev=08134168c75e4a4ca4917d6c0dbf835e&t=20241212T112222Z&hash=B98C1F8EBEB956999AFCD92E5F5D350A" rel="stylesheet" /> <script src="/Scripts/jquery3.5.1.min.js"></script>  </head> <body class="header--dark navigation__primary--dark default-device vanilla-modal bodyclass" data-taxonomy-page=""> <div id="wrapper">   <div class="component header-site-furniture component-content"> <div class="component navigation-functional component-content"> <nav class="navigation-functional" aria-label="Support"> <div class="row"> <div class="columns small-12 remove-gutter-for-small"> <ul> <li class="navigation-functional__list-item "> <a href="/en/footer-links/contact" class=" " title=""><span>Contact</span></a> </li> <li class="navigation-functional__list-item "> <a href="/en/press-room" class=" " title="Press Room"><span>Press Room</span></a> </li> <li class="navigation-functional__list-item navigation-functional__search-item"> <a class="navigation__search-trigger icon" href="/#search-box"> <span>Search</span></a> </li> <li class="navigation-functional__list-item"> </li> <li class="navigation-functional__list-item"> </li> <li class="navigation-functional__list-item navigation-functional__list-item--language-selector"> <a class=" country-selector-icon language-selector-dropdown-trigger" aria-expanded="false" aria-haspopup="true" aria-controls="dropdown__languageSelection" tabindex="0" href="/#"> <span>Country</span> </a> <ul class="language-selector-dropdown" id="dropdown__languageSelection" role="menu"> <li> <a href="https://www.grunenthal.at" ><img src="/-/media/projects/shared/flags/country-selector/de-at.png?rev=5719d0edc2c147bb9fa2a2bbd5b75d74" alt="Flag" width="24" height="18" /> Austria</a> </li> <li> <a href="http://www.grunenthal.com.br" ><img src="/-/media/projects/shared/flags/country-selector/pt-br.png?rev=9f020884c2d641d7b6389676f086269d" alt="Flag" width="24" height="18" /> Brazil</a> </li> <li> <a href="https://www.grunenthal.cl" ><img src="/-/media/projects/shared/flags/country-selector/es-cl.png?rev=2f8bffba8fe0462c96517ac2bb5c8246" alt="Flag" width="24" height="18" /> Chile</a> </li> <li> <a href="https://www.grunenthal.com.co" ><img src="/-/media/projects/shared/flags/country-selector/es-co.png?rev=a15bfc13b0234ac9ac164a7d13e730fc" alt="Flag" width="24" height="18" /> Colombia</a> </li> <li> <a href="http://www.grunenthal.com.ec" ><img src="/-/temp//iconcache/flags/32x32/flag_equador.png.aspx" alt="Flag" width="24" height="18" /> Ecuador</a> </li> <li> <a href="https://www.grunenthal.fr" ><img src="/-/media/projects/shared/flags/country-selector/fr-fr.png?rev=5e8c0b5b6b544a16afbcf525c93371f3" alt="Flag" width="24" height="18" /> France</a> </li> <li> <a href="https://www.grunenthal.de" ><img src="/-/media/projects/shared/flags/country-selector/de-de.png?rev=6be20996be784101bd2a3b00393a452a" alt="Flag" width="24" height="18" /> Germany</a> </li> <li> <a href="https://www.grunenthal.co.uk" ><img src="/-/media/projects/shared/flags/country-selector/en-gb.png?rev=be5e7a85751344cd8660ef84818b51c4" alt="Flag" width="24" height="18" /> Great Britain</a> </li> <li> <a href="https://www.grunenthal.ie" ><img src="/-/media/projects/shared/flags/country-selector/en-ie.png?rev=c38a173106934c9999095b87409c4fe5" alt="Flag" width="24" height="18" /> Ireland</a> </li> <li> <a href="https://www.grunenthal.it" ><img src="/-/media/projects/shared/flags/country-selector/it-it.png?rev=6fb1f41ed014488eb9d4f3d03b583e2b" alt="Flag" width="24" height="18" /> Italy</a> </li> <li> <a href="http://www.grunenthal.com.mx" ><img src="/-/media/projects/shared/flags/country-selector/es-mx.png?rev=4eed4f4add764de99c7f20661d7e7645" alt="Flag" width="24" height="18" /> Mexico</a> </li> <li> <a href="https://www.grunenthal.nl" ><img src="/-/media/projects/shared/flags/country-selector/nl-nl.png?rev=375fcc38271a44ab9072002a636defbb" alt="Flag" width="24" height="18" /> Netherlands</a> </li> <li> <a href="http://www.grunenthal.com.pe" ><img src="/-/media/projects/shared/flags/country-selector/es-pe.png?rev=45eef722726248339a3dc28eafa026ae" alt="Flag" width="24" height="18" /> Peru</a> </li> <li> <a href="https://www.grunenthal.pt" ><img src="/-/media/projects/shared/flags/country-selector/pt-pt.png?rev=ca8080f7f93e4aa5951a58a5e7545222" alt="Flag" width="24" height="18" /> Portugal</a> </li> <li> <a href="https://www.grunenthal.es" ><img src="/-/media/projects/shared/flags/country-selector/es-es.png?rev=0a84c2c7c5f3409896d297ecf7042d07" alt="Flag" width="24" height="18" /> Spain</a> </li> <li> <a href="https://www.grunenthal.ch" ><img src="/-/media/projects/shared/flags/country-selector/swiss_64x64px.png?rev=044d013030024b4eaf38a6e11652173d" alt="Flag" width="24" height="18" /> Switzerland</a> </li> </ul> <script> var triggerSelector = '.language-selector-dropdown-trigger'; var attr = 'aria-expanded'; var valTrue = 'true'; var valFalse = 'false'; window.addEventListener('click', function (event) { var dropdown = event.target.closest('.language-selector-dropdown'); if (dropdown) return; var languageDropdownTrigger = event.target.closest(triggerSelector); if (languageDropdownTrigger) { var dropdown = document.getElementById(languageDropdownTrigger.getAttribute('aria-controls')); if (dropdown && languageDropdownTrigger.nextElementSibling !== dropdown) { languageDropdownTrigger.parentNode.insertBefore( dropdown, languageDropdownTrigger.nextElementSibling, ); // wait a frame synchronously dropdown.offsetTop; } event.preventDefault(); languageDropdownTrigger.setAttribute( attr, languageDropdownTrigger.getAttribute(attr) === valTrue ? valFalse : valTrue, ); return; } document.querySelectorAll(triggerSelector).forEach(function (languageDropdownTrigger) { languageDropdownTrigger.setAttribute(attr, valFalse); }); }); </script> </li> </ul> </div> </div> </nav> </div> <header id="siteHeader"> <div class="row"> <div class="large-3 small-9 columns"> <a class="logo" href="/" title="Home"></a> </div> <div class="large-3 columns"> <ul class="header__buttons"> <li> <a class=" country-selector-icon navigation__language-trigger language-selector-dropdown-trigger" aria-expanded="false" aria-haspopup="true" aria-controls="dropdown__languageSelection" tabindex="0" href="/#"></a> </li> <li><a class="navigation__search-trigger icon" href="/#cd-search"></a></li> <li><a class="navigation__nav-trigger icon" href="/#cd-primary-nav"></a></li> </ul> </div> </div> <nav class="navigation" aria-label="Top"> <div class="nav-content"> <div class="row"> <div class="columns small-12 remove-gutter-for-small">  <ul role="menu" id="navigation__primary" class="navigation__primary is-fixed "> <li role="none" class="has-children"> <a title="A World Free of Pain" aria-controls="nav-section--1" role="menuitem" aria-haspopup="true" aria-expanded="false" href="/#" class="" data-show="#nav-section--1" data-mobile-href="/en/world-free-of-pain"> A World Free of Pain <i class="icon-navigation-dropdown"></i> <ul role="menu" class="navigation__secondary mobile-only" style="display: none;"></ul> </a> </li> <li role="none" class="has-children"> <a title="Company" aria-controls="nav-section--2" role="menuitem" aria-haspopup="true" aria-expanded="false" href="/#" class="" data-show="#nav-section--2" data-mobile-href="/en/company"> Company <i class="icon-navigation-dropdown"></i> <ul role="menu" class="navigation__secondary mobile-only" style="display: none;"></ul> </a> </li> <li role="none" class="has-children"> <a title="Responsibility" aria-controls="nav-section--3" role="menuitem" aria-haspopup="true" aria-expanded="false" href="/#" class="" data-show="#nav-section--3" data-mobile-href="/en/responsibility"> Responsibility <i class="icon-navigation-dropdown"></i> <ul role="menu" class="navigation__secondary mobile-only" style="display: none;"></ul> </a> </li> <li role="none" class="has-children"> <a title="Science" aria-controls="nav-section--4" role="menuitem" aria-haspopup="true" aria-expanded="false" href="/#" class="currentlyOpened" data-show="#nav-section--4" data-mobile-href="/en/science"> Science <i class="icon-navigation-dropdown"></i> <ul role="menu" class="navigation__secondary mobile-only" style="display: none;"></ul> </a> </li> <li role="none" > <a title="Careers" aria-controls="nav-section--5" role="menuitem" aria-haspopup="false" aria-expanded="false" href="/en/careers" class="" data-show="#nav-section--5" data-mobile-href="/en/careers"> Careers </a> </li> <li role="none" > <a title="Creditors" aria-controls="nav-section--6" role="menuitem" aria-haspopup="false" aria-expanded="false" href="https://creditors.grunenthal.com/" class="" data-show="#nav-section--6" data-mobile-href="https://creditors.grunenthal.com/"> Creditors </a> </li> <li role="none" class="has-children"> <a title="Media" aria-controls="nav-section--7" role="menuitem" aria-haspopup="true" aria-expanded="false" href="/#" class="" data-show="#nav-section--7" data-mobile-href="/en/press-room"> Media <i class="icon-navigation-dropdown"></i> <ul role="menu" class="navigation__secondary mobile-only" style="display: none;"></ul> </a> </li> </ul>  </div> </div> </div> </nav> <div class="navigation__secondary-panel"> <div id="nav-section--1" class="nav-section" style="display: none;"> <div class="row flex"> <div class="columns medium-3 nav-2nd-level"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-section--1-1" class="sub-nav-link" data-mobile-href="/en/world-free-of-pain/understanding-pain"> <a href ="/en/world-free-of-pain/understanding-pain" role="menuitem"> Understanding Pain </a> </li> <li role="none" data-show="#nav-sub-section--1-2" class="sub-nav-link" data-mobile-href="/en/world-free-of-pain/pain-insights"> <a class="hasChildren" href ="#" role="menuitem"> Pain Insights <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--1-3" class="sub-nav-link" data-mobile-href="/en/world-free-of-pain/pain-management"> <a href ="/en/world-free-of-pain/pain-management" role="menuitem"> Pain Management </a> </li> <li role="none" data-show="#nav-sub-section--1-4" class="sub-nav-link" data-mobile-href="/en/world-free-of-pain/initiatives"> <a class="hasChildren" href ="#" role="menuitem"> Initiatives & Grants <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--1-5" class="sub-nav-link" data-mobile-href="/en/world-free-of-pain/patient-collaboration"> <a href ="/en/world-free-of-pain/patient-collaboration" role="menuitem"> Patient Collaborations </a> </li> </ul> </div> </div> <div class="columns medium-9 nav-3rd-level"> <div id="nav-sub-section--1-0" class="nav-sub-section min-height-100"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and our vision is a world free of pain. Innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs. <br /><br /> <a href="/en/world-free-of-pain" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> A World Free of Pain</a> </div> </div> </div> </div> <div id="nav-sub-section--1-1" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> <br /><br /> <a href="/en/world-free-of-pain/understanding-pain" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Understanding Pain</a> </div> </div> </div> </div> <div id="nav-sub-section--1-2" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-2--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/world-free-of-pain/pain-insights/pain-basics/definition-of-pain" class=""> Pain Basics </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/world-free-of-pain/pain-insights/key-pain-conditions" class=""> Key Pain Conditions </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Learn about the essentials behind pain and gain in-depth knowledge on key pain conditions with high unmet needs.<br class="t-last-br" /> <br /><br /> <a href="/en/world-free-of-pain/pain-insights" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Pain Insights</a> </div> </div> </div> </div> <div id="nav-sub-section--1-3" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> <br /><br /> <a href="/en/world-free-of-pain/pain-management" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Pain Management</a> </div> </div> </div> </div> <div id="nav-sub-section--1-4" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-4--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/world-free-of-pain/initiatives/change-pain" class=""> Change Pain </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/world-free-of-pain/initiatives/e-g-g" class=""> EFIC-Grünenthal-Grant </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital. <br /><br /> <a href="/en/world-free-of-pain/initiatives" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Initiatives & Grants</a> </div> </div> </div> </div> <div id="nav-sub-section--1-5" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal is committed to embedding patient engagement through each stage in the lifecycle of our medicines and beyond. <br /><br /> <a href="/en/world-free-of-pain/patient-collaboration" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Patient Collaborations</a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="navigation__secondary-panel"> <div id="nav-section--2" class="nav-section" style="display: none;"> <div class="row flex"> <div class="columns medium-3 nav-2nd-level"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-section--2-1" class="sub-nav-link" data-mobile-href="/en/company/we-are-gruenenthal"> <a href ="/en/company/we-are-gruenenthal" role="menuitem"> We are Grünenthal </a> </li> <li role="none" data-show="#nav-sub-section--2-2" class="sub-nav-link" data-mobile-href="/en/company/leadership"> <a href ="/en/company/leadership" role="menuitem"> Leadership </a> </li> <li role="none" data-show="#nav-sub-section--2-3" class="sub-nav-link" data-mobile-href="/en/company/supervisory-board"> <a href ="/en/company/supervisory-board" role="menuitem"> Supervisory Board </a> </li> <li role="none" data-show="#nav-sub-section--2-4" class="sub-nav-link" data-mobile-href="/en/company/partnering"> <a class="hasChildren" href ="#" role="menuitem"> Partnering <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--2-5" class="sub-nav-link" data-mobile-href="/en/company/global-capabilities"> <a class="hasChildren" href ="#" role="menuitem"> Global presence & sites <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--2-6" class="sub-nav-link" data-mobile-href="/en/company/products"> <a href ="/en/company/products" role="menuitem"> Products </a> </li> <li role="none" data-show="#nav-sub-section--2-7" class="sub-nav-link" data-mobile-href="/en/company/history"> <a href ="/en/company/history" role="menuitem"> History </a> </li> </ul> </div> </div> <div class="columns medium-9 nav-3rd-level"> <div id="nav-sub-section--2-0" class="nav-sub-section min-height-100"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs. <br /><br /> <a href="/en/company" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Company</a> </div> </div> </div> </div> <div id="nav-sub-section--2-1" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us. <br /><br /> <a href="/en/company/we-are-gruenenthal" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> We are Grünenthal</a> </div> </div> </div> </div> <div id="nav-sub-section--2-2" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> <p><strong></strong>A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.</p> <br /><br /> <a href="/en/company/leadership" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Leadership</a> </div> </div> </div> </div> <div id="nav-sub-section--2-3" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit. <br /><br /> <a href="/en/company/supervisory-board" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Supervisory Board</a> </div> </div> </div> </div> <div id="nav-sub-section--2-4" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-4--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/partnering/areas-of-interest" class=""> Areas of interest </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/partnering/public-private-partnerships" class=""> Public Private Partnerships </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--3" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/partnering/contract-manufacturing-services" class=""> Contract Manufacturing Business </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs. <br /><br /> <a href="/en/company/partnering" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Partnering</a> </div> </div> </div> </div> <div id="nav-sub-section--2-5" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-5--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/global-capabilities/affiliates-asia" class=""> Affiliates in Asia </a> </li> <li role="none" data-show="#nav-sub-sub-section-5--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/global-capabilities/affiliates-europe" class=""> Affiliates in Europe </a> </li> <li role="none" data-show="#nav-sub-sub-section-5--3" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/global-capabilities/affiliates-usa-latin-america" class=""> Affiliates in the USA & Latin America </a> </li> <li role="none" data-show="#nav-sub-sub-section-5--4" class="sub-sub-nav-link"> <a role="menuitem" href="/en/company/global-capabilities/manufacturing-sites" class=""> Manufacturing Sites </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond. <br /><br /> <a href="/en/company/global-capabilities" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Global presence & sites</a> </div> </div> </div> </div> <div id="nav-sub-section--2-6" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal’s product portfolio, brands, ingredients and indication range. <br /><br /> <a href="/en/company/products" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Products</a> </div> </div> </div> </div> <div id="nav-sub-section--2-7" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Although firmly rooted in Germany, today we are very much a growing global Business. <br /><br /> <a href="/en/company/history" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> History</a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="navigation__secondary-panel"> <div id="nav-section--3" class="nav-section" style="display: none;"> <div class="row flex"> <div class="columns medium-3 nav-2nd-level"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-section--3-1" class="sub-nav-link" data-mobile-href="/en/responsibility/corporate-responsibility-programme"> <a class="hasChildren" href ="#" role="menuitem"> Our Corporate Responsibility Programme <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--3-2" class="sub-nav-link" data-mobile-href="/en/responsibility/compliance-ethics-transparency"> <a href ="/en/responsibility/compliance-ethics-transparency" role="menuitem"> Compliance, Ethics and Transparency </a> </li> <li role="none" data-show="#nav-sub-section--3-3" class="sub-nav-link" data-mobile-href="/en/responsibility/patient-support"> <a class="hasChildren" href ="#" role="menuitem"> Patient – How we support patients in need <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--3-4" class="sub-nav-link" data-mobile-href="/en/responsibility/people-employees-partners-communities"> <a class="hasChildren" href ="#" role="menuitem"> People – How we work with employees, partners and communities <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--3-5" class="sub-nav-link" data-mobile-href="/en/responsibility/planet-sustainability-approach"> <a class="hasChildren" href ="#" role="menuitem"> Planet – What we do for a sustainable future <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--3-6" class="sub-nav-link" data-mobile-href="/en/responsibility/responsible-sourcing"> <a href ="/en/responsibility/responsible-sourcing" role="menuitem"> Responsible Sourcing </a> </li> <li role="none" data-show="#nav-sub-section--3-7" class="sub-nav-link" data-mobile-href="/en/responsibility/thalidomide"> <a href ="/en/responsibility/thalidomide" role="menuitem"> Thalidomide </a> </li> </ul> </div> </div> <div class="columns medium-9 nav-3rd-level"> <div id="nav-sub-section--3-0" class="nav-sub-section min-height-100"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> As a global leader in pain management, conducting business responsibly is a core part of our company’s strategy and culture. We provide transparent responsibility and sustainability reporting on our progress, and an independent agency regularly rates our performance according to environmental, social and governance (ESG) criteria. We join forces for sustainability and are committed to supporting the United Nations Sustainable Development Goals (SDGs). <br /><br /> <a href="/en/responsibility" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Responsibility</a> </div> </div> </div> </div> <div id="nav-sub-section--3-1" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-1--1" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/corporate-responsibility-programme#oneapproach" class=""> One strategic approach </a> </li> <li role="none" data-show="#nav-sub-sub-section-1--2" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/corporate-responsibility-programme#fieldsofaction" class=""> Four fields of action to ensure maximum positive impact </a> </li> <li role="none" data-show="#nav-sub-sub-section-1--3" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/corporate-responsibility-programme#twelvekeytopics" class=""> Twelve key topics with clear targets </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Corporate responsibility is at the core of our business strategy and culture. It runs through everything we do. We want to create a net positive impact for patients, employees, partners and wider society, and work towards reducing our impact on the environment. <br /><br /> <a href="/en/responsibility/corporate-responsibility-programme" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Our Corporate Responsibility Programme</a> </div> </div> </div> </div> <div id="nav-sub-section--3-2" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> We believe compliance, ethics and transparency go hand in hand. Excellence in this area is a key topic for us – and is deeply anchored in our culture. <br /><br /> <a href="/en/responsibility/compliance-ethics-transparency" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Compliance, Ethics and Transparency</a> </div> </div> </div> </div> <div id="nav-sub-section--3-3" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-3--1" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/patient-support#responsibleuse" class=""> Responsible Use of Pain Medication </a> </li> <li role="none" data-show="#nav-sub-sub-section-3--2" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/patient-support#awarenessaccessibility" class=""> Awareness & Accessibility </a> </li> <li role="none" data-show="#nav-sub-sub-section-3--3" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/patient-support#responsibleinnovation" class=""> Responsible Innovation </a> </li> <li role="none" data-show="#nav-sub-sub-section-3--4" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/patient-support#governancesafety" class=""> Product Governance & Safety </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Having access to appropriate pain treatment is a basic human right. As a leader in pain management, we help to educate healthcare professionals and patients on how to use these medicines responsibly. We also raise awareness and increase accessibility to current treatments while developing new medicines for unmet medical needs. <br /><br /> <a href="/en/responsibility/patient-support" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Patient – How we support patients in need</a> </div> </div> </div> </div> <div id="nav-sub-section--3-4" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-4--1" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/people-employees-partners-communities#human-capital-fairness" target="_blank" class=""> Human Capital Fairness </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--2" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/people-employees-partners-communities#equality-diversity-inclusion" target="_blank" class=""> Equality, Diversity and Inclusion </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--3" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/people-employees-partners-communities#attractive-employer" target="_blank" class=""> Attractive Employer </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--4" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/people-employees-partners-communities#employee-engagement" target="_blank" class=""> Employee Engagement </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> How can we have a positive impact on the lives of the people we work with, our partners and wider society? Find out what we do to foster trust and promote diversity and inclusion, how we empower our employees to be their best and look after their health and wellbeing, and how we contribute to improving the quality of life for people and communities around us. <br /><br /> <a href="/en/responsibility/people-employees-partners-communities" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> People – How we work with employees, partners and communities</a> </div> </div> </div> </div> <div id="nav-sub-section--3-5" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-5--1" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/planet-sustainability-approach#environmental-excellence-strategy" class=""> Environmental Excellence Strategy </a> </li> <li role="none" data-show="#nav-sub-sub-section-5--2" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/planet-sustainability-approach#responsible-use-of-resources" class=""> Responsible Use of Resources </a> </li> <li role="none" data-show="#nav-sub-sub-section-5--3" class="sub-sub-nav-link"> <a role="menuitem" href="https://www.grunenthal.com/en/responsibility/planet-sustainability-approach#climate-impact" class=""> Our Impact on Climate </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> We join together with our employees, partners and customers to reduce our carbon footprint, save energy and resources, and decrease waste in our value chain. <br /><br /> <a href="/en/responsibility/planet-sustainability-approach" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Planet – What we do for a sustainable future</a> </div> </div> </div> </div> <div id="nav-sub-section--3-6" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> The Grünenthal Responsible Sourcing Programme will increase transparency and help create a positive ESG impact in our supply chain and connected local communities. <br /><br /> <a href="/en/responsibility/responsible-sourcing" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Responsible Sourcing</a> </div> </div> </div> </div> <div id="nav-sub-section--3-7" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> <br /><br /> <a href="/en/responsibility/thalidomide" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Thalidomide</a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="navigation__secondary-panel"> <div id="nav-section--4" class="nav-section" style="display: none;"> <div class="row flex"> <div class="columns medium-3 nav-2nd-level"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-section--4-1" class="sub-nav-link" data-mobile-href="/en/science/pain-research-and-development"> <a class="hasChildren" href ="#" role="menuitem"> R&D approach <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--4-2" class="sub-nav-link" data-mobile-href="/en/science/research-and-development-collaboration"> <a href ="/en/science/research-and-development-collaboration" role="menuitem"> Collaboration </a> </li> <li role="none" data-show="#nav-sub-section--4-3" class="sub-nav-link" data-mobile-href="/en/science/pipeline"> <a class="hasChildren" href ="#" role="menuitem"> Pipeline <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--4-4" class="sub-nav-link" data-mobile-href="/en/science/therapeutic-areas"> <a class="hasChildren" href ="#" role="menuitem"> Therapeutic areas <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--4-5" class="sub-nav-link" data-mobile-href="/en/science/clinical-trials"> <a class="hasChildren currentlyOpened" href ="#" role="menuitem"> Clinical trials <i class="icon-right"></i> </a> </li> </ul> </div> </div> <div class="columns medium-9 nav-3rd-level"> <div id="nav-sub-section--4-0" class="nav-sub-section min-height-100"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Our company has a clear vision of a world free of pain and we maintain a laser-sharp focus on this vision in everything we do – especially in our research and development activities. <br /><br /> <a href="/en/science" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Science</a> </div> </div> </div> </div> <div id="nav-sub-section--4-1" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-1--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/pain-research-and-development/innovation-hubs" class=""> Innovation Hubs </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> We follow a holistic and solution-agnostic approach to deliver highly effective pain treatments, building our programmes on a firm foundation of human pathophysiology and solid human target validation. <br /><br /> <a href="/en/science/pain-research-and-development" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> R&D approach</a> </div> </div> </div> </div> <div id="nav-sub-section--4-2" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> <br /><br /> <a href="/en/science/research-and-development-collaboration" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Collaboration </a> </div> </div> </div> </div> <div id="nav-sub-section--4-3" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-3--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/pipeline/rtx" class=""> RTX (Resiniferatoxin) </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> To move closer to our vision of a world free of pain, we are currently pursuing a range of programmes across different modalities, targets and mechanisms of action. <br /><br /> <a href="/en/science/pipeline" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Pipeline </a> </div> </div> </div> </div> <div id="nav-sub-section--4-4" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-4--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/therapeutic-areas/peripheral-neuropathic-pain" class=""> Peripheral neuropathic pain </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/therapeutic-areas/chronic-post-surgical-pain" class=""> Chronic post-surgical pain </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--3" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/therapeutic-areas/chronic-low-back-pain" class=""> Chronic low back pain </a> </li> <li role="none" data-show="#nav-sub-sub-section-4--4" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/therapeutic-areas/osteoarthritis" class=""> Osteoarthritis  </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal is pursuing four key pain indications: peripheral neuropathic pain, chronic postoperative pain, chronic low back pain, and osteoarthritis. <br /><br /> <a href="/en/science/therapeutic-areas" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Therapeutic areas</a> </div> </div> </div> </div> <div id="nav-sub-section--4-5" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-5--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/clinical-trials/data-clinical-trials" class="currentlyOpened"> Clinical trial portal </a> </li> <li role="none" data-show="#nav-sub-sub-section-5--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/science/clinical-trials/data-sharing-clinical-trials" class=""> Clinical data sharing </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available. <br /><br /> <a href="/en/science/clinical-trials" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Clinical trials</a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="navigation__secondary-panel"> <div id="nav-section--7" class="nav-section" style="display: none;"> <div class="row flex"> <div class="columns medium-3 nav-2nd-level"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-section--7-1" class="sub-nav-link" data-mobile-href="/en/press-room/stories"> <a href ="/en/press-room/stories" role="menuitem"> Our Stories </a> </li> <li role="none" data-show="#nav-sub-section--7-2" class="sub-nav-link" data-mobile-href="/en/press-room/press-releases/2025"> <a class="hasChildren" href ="#" role="menuitem"> Press releases <i class="icon-right"></i> </a> </li> <li role="none" data-show="#nav-sub-section--7-3" class="sub-nav-link" data-mobile-href="/en/press-room/statements"> <a href ="/en/press-room/statements" role="menuitem"> Statements </a> </li> <li role="none" data-show="#nav-sub-section--7-4" class="sub-nav-link" data-mobile-href="/en/press-room/corporate-publications"> <a href ="/en/press-room/corporate-publications" role="menuitem"> Corporate publications </a> </li> <li role="none" data-show="#nav-sub-section--7-5" class="sub-nav-link" data-mobile-href="/en/press-room/resources-image"> <a href ="/en/press-room/resources-image" role="menuitem"> Image resources </a> </li> <li role="none" data-show="#nav-sub-section--7-6" class="sub-nav-link" data-mobile-href="/en/press-room/resources-video"> <a href ="/en/press-room/resources-video" role="menuitem"> Video resources </a> </li> </ul> </div> </div> <div class="columns medium-9 nav-3rd-level"> <div id="nav-sub-section--7-0" class="nav-sub-section min-height-100"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Explore our media section and access a range of materials relating to our company, people, medicines and medical devices. <br /><br /> <a href="/en/press-room" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Media</a> </div> </div> </div> </div> <div id="nav-sub-section--7-1" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us. <br /><br /> <a href="/en/press-room/stories" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Our Stories </a> </div> </div> </div> </div> <div id="nav-sub-section--7-2" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-4"> <div class="nav-section__menu"> <ul role="menu"> <li role="none" data-show="#nav-sub-sub-section-2--1" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2025" class=""> 2025 </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--2" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2024" class=""> 2024 </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--3" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2023" class=""> 2023 </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--4" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2022" class=""> 2022 </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--5" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2021" class=""> 2021 </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--6" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2020" class=""> 2020 </a> </li> <li role="none" data-show="#nav-sub-sub-section-2--7" class="sub-sub-nav-link"> <a role="menuitem" href="/en/press-room/press-releases/2019" class=""> 2019 </a> </li> </ul> </div> </div> <div class="columns medium-8"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany. <br /><br /> <a href="/en/press-room/press-releases/2025" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Press releases</a> </div> </div> </div> </div> <div id="nav-sub-section--7-3" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> <br /><br /> <a href="/en/press-room/statements" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Statements</a> </div> </div> </div> </div> <div id="nav-sub-section--7-4" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. . <br /><br /> <a href="/en/press-room/corporate-publications" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Corporate publications</a> </div> </div> </div> </div> <div id="nav-sub-section--7-5" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures. <br /><br /> <a href="/en/press-room/resources-image" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Image resources </a> </div> </div> </div> </div> <div id="nav-sub-section--7-6" class="nav-sub-section min-height-100" style="display: none;"> <div class="columns medium-12"> <div class="nav-section__content" style="background-image: url('')"> <div class="nav-section__text"> The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting. <br /><br /> <a href="/en/press-room/resources-video" class="button button-p1" role="button"><span class="icon-right"></span> <span class="button__elipsis">...</span> Video resources </a> </div> </div> </div> </div> </div> </div> </div> </div> <div id="search-header" class="search-header"> <form> <i class="icon-magnify-glass"></i> <div class="component search-box search-header" data-properties='{"endpoint":"/en/sxa/search/results/","suggestionEndpoint":"/en/sxa/search/suggestions/","suggestionsMode":"ShowSearchResults","resultPage":"/en/searchresults","targetSignature":"","v":"{4C46236D-8ECA-4A39-9FB9-A8E47DE0EA6D}","s":"{6E567687-8BD2-4C66-9808-C7977B9F904F}","p":5,"l":"","languageSource":"AllLanguages","searchResultsSignature":"","itemid":"{98010A3C-884E-4B5A-8826-A2C8A0B54249}","minSuggestionsTriggerCharacterCount":2}'> <div class="component-content"> <label for="textBoxSearch"> Search results </label> <input type="text" class="search-box-input" autocomplete="off" name="textBoxSearch" maxlength="100" placeholder="Search here..." /> <button class="search-box-button-with-redirect" type="submit"> Search </button> </div> </div> </form> </div> </header> </div> <div id="content">   <div class="component component-content"> <div class="hero-text "> <div class="row hero-text-content"> <div class="small-12 large-8 columns hero-text-content__headline"> <nav class="breadcrumbs breadcrumbs--absolute"> <ol> <li class="selected"> <a class="button__elipsis" href="#">...</a> <span class="icon-right"></span> <a href="/en/science">Science</a> </li> </ol> </nav> <h1 class="heading00 text--nori heading00--no-margin"> Grünenthal Clinical Trial Portal <br /> </h1> </div> </div> </div> </div>  <div class="component row-splitter"> <div class=" small-spacer-xl"> <div class="row"> <div class="component column-splitter " > <div class="small-12 medium-2 columns"> </div> <div class="small-12 medium-8 columns"> <div id="" class="component component-content ">  <div class="richtext richtext--standard"> <p class="lead"> As a research-based pharmaceutical company, Grünenthal recognizes the importance of publicly registering clinical trials and making information including results available. Please consult the table below to easily find information on Grünenthal sponsored clinical trials. </p> </div>  </div> </div> <div class="small-12 medium-2 columns"> </div> </div> </div> </div> <div class=" spacer-xl"> <div class="row"> <div class="component column-splitter " > <div class="small-12 medium-12 columns"> <div class="component column-splitter " > <div class="small-12 medium-12 columns"> <div class="component gcclinicaltrialtable component-content"> <div class="columns small-12"> <table class="clinicalTrialTable" data-page="1" aria-describedby="mydesc"> <thead> <tr> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="clinical-trial-id" type="text" placeholder="Enter Number..." /></th> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="sponsor-substance-code" type="text" placeholder="Enter Product..." /></th> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="trial-indication" type="text" placeholder="Enter Condition..." /></th> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="brief-title" type="text" placeholder="Enter Brief Title Column..." /></th> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="trial-phase" type="text" placeholder="Enter Phase..." /></th> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="trial-status" type="text" placeholder="Enter Status..." /></th> <th scope="col"><input class="clinicalTrialFilter form-control" data-filter-for="results-posted" type="text" placeholder="Enter Results..." /></th> </tr> <tr> <th scope="col">Number</th> <th scope="col">Product</th> <th scope="col">Condition</th> <th scope="col">Brief Title Column</th> <th scope="col">Phase</th> <th scope="col">Status</th> <th scope="col">Results</th> </tr> </thead> <tbody> <tr class="clinicalTrialRow" data-clinical-trial-id="" data-sponsor-substance-code="" data-trial-indication="" data-brief-title="" data-trial-phase="" data-trial-status="" data-results-posted="No" > <td><a data-clinical-trial-item-id="e876e6ac-12ad-41d0-b243-92081a8b45be"></a></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF10004/01" data-sponsor-substance-code="5% Lidocaine medicated plaster" data-trial-indication="Postherpetic neuralgia" data-brief-title="" data-trial-phase="3" data-trial-status="Completed" data-results-posted="No" > <td><a data-clinical-trial-item-id="31647c0e-73c5-4684-8fc3-db8f686e9078">KF10004/01</a></td> <td>5% Lidocaine medicated plaster</td> <td>Postherpetic neuralgia</td> <td></td> <td>3</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF10004/02" data-sponsor-substance-code="5% Lidocaine medicated plaster" data-trial-indication="Postherpetic neuralgia" data-brief-title="" data-trial-phase="3" data-trial-status="Completed" data-results-posted="No" > <td><a data-clinical-trial-item-id="a105ddb1-d77b-41d7-bbd8-f055322c871b">KF10004/02</a></td> <td>5% Lidocaine medicated plaster</td> <td>Postherpetic neuralgia</td> <td></td> <td>3</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF10004/10" data-sponsor-substance-code="5% Lidocaine medicated plaster" data-trial-indication="Localized chronic post-operative neuropathic pain" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" > <td><a data-clinical-trial-item-id="2f5650cb-0f21-42ad-8beb-6d5affa059c7">KF10004/10</a></td> <td>5% Lidocaine medicated plaster</td> <td>Localized chronic post-operative neuropathic pain</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="EN3324-201" data-sponsor-substance-code="Axomadol" data-trial-indication="Moderate to severe chronic low back pain" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="No" > <td><a data-clinical-trial-item-id="ec5d6094-6d27-45e0-bb5f-33caf049d69e">EN3324-201</a></td> <td>Axomadol</td> <td>Moderate to severe chronic low back pain</td> <td>--</td> <td>2</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP0151Y/09" data-sponsor-substance-code="Axomadol" data-trial-indication="--" data-brief-title="A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" > <td><a data-clinical-trial-item-id="cafb44bf-02a3-4b07-9805-7f94704a0e97">HP0151Y/09</a></td> <td>Axomadol</td> <td>--</td> <td>A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP0151Y/10" data-sponsor-substance-code="Axomadol" data-trial-indication="--" data-brief-title="A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" > <td><a data-clinical-trial-item-id="bddb4f05-e7ed-4df8-99c6-77f4ec97066d">HP0151Y/10</a></td> <td>Axomadol</td> <td>--</td> <td>A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP0151Y/13" data-sponsor-substance-code="Axomadol" data-trial-indication="--" data-brief-title="A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" > <td><a data-clinical-trial-item-id="d002f4cd-fd59-440e-8872-ee4fd66d0d32">HP0151Y/13</a></td> <td>Axomadol</td> <td>--</td> <td>A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF0151Y/06" data-sponsor-substance-code="Axomadol" data-trial-indication="Postoperative pain following tonsillectomy" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" > <td><a data-clinical-trial-item-id="bf2cd48c-33d4-424c-8829-46565341df39">KF0151Y/06</a></td> <td>Axomadol</td> <td>Postoperative pain following tonsillectomy</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF0151Y/07" data-sponsor-substance-code="Axomadol" data-trial-indication="Chronic knee-joint osteoarthritis" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" > <td><a data-clinical-trial-item-id="ed0d5155-d07c-48f6-bf01-ceff7ada9b18">KF0151Y/07</a></td> <td>Axomadol</td> <td>Chronic knee-joint osteoarthritis</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5303/04" data-sponsor-substance-code="Burprenorphine" data-trial-indication="--" data-brief-title="Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="f9133c4a-005d-4358-a9b1-875e89daf12e">HP5303/04</a></td> <td>Burprenorphine</td> <td>--</td> <td>Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5303/05" data-sponsor-substance-code="Burprenorphine" data-trial-indication="--" data-brief-title="Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="aaf9c08e-cd80-42f8-b467-1b3ec10c0d7b">HP5303/05</a></td> <td>Burprenorphine</td> <td>--</td> <td>Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5303/01" data-sponsor-substance-code="Burprenorphine" data-trial-indication="Moderate to severe chronic pain" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="61362129-25cd-4d17-ae0c-0fc205cc416e">KF5303/01</a></td> <td>Burprenorphine</td> <td>Moderate to severe chronic pain</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="GRT-PK-07" data-sponsor-substance-code="Cebranopadol" data-trial-indication="--" data-brief-title="A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="ecb450ad-c207-4a6a-993e-977fb19fc4e4">GRT-PK-07</a></td> <td>Cebranopadol</td> <td>--</td> <td>A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP6005/10" data-sponsor-substance-code="Cebranopadol" data-trial-indication="--" data-brief-title="A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users" data-trial-phase="" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="18cefee5-59e9-45b9-aed6-d1e3195655b9">HP6005/10</a></td> <td>Cebranopadol</td> <td>--</td> <td>A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users</td> <td></td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/01" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Moderate to severe pain following bunionectomy" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="b40264c6-4bf2-4601-9458-c4b449a03714">KF6005/01</a></td> <td>Cebranopadol</td> <td>Moderate to severe pain following bunionectomy</td> <td>--</td> <td>2</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/02" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Pain due to diabetic polyneuropathy" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="c064263a-97aa-4443-8737-97118dcdc31e">KF6005/02</a></td> <td>Cebranopadol</td> <td>Pain due to diabetic polyneuropathy</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/03" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Moderate to severe pain due to OA of the knee" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="8a87a213-3fec-414d-8f8d-996ae1419650">KF6005/03</a></td> <td>Cebranopadol</td> <td>Moderate to severe pain due to OA of the knee</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/04" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Moderate to severe pain due to diabetic polyneuropathy" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="a2a44a5e-12d0-4bb1-b9bd-9c140e747812">KF6005/04</a></td> <td>Cebranopadol</td> <td>Moderate to severe pain due to diabetic polyneuropathy</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/06" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Low back pain" data-brief-title="Efficacy and safety of GRT6005 in patients with chronic low back pain" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="5472e711-acc3-410a-9a11-633d23d86482">KF6005/06</a></td> <td>Cebranopadol</td> <td>Low back pain</td> <td>Efficacy and safety of GRT6005 in patients with chronic low back pain</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/07" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Chronic moderate to severe pain related to cancer" data-brief-title="CORAL - Cebranopadol versus morphine prolonged-release in patients with chronic moderate to severe pain related to cancer" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="20f6cedd-8bb1-420a-9ee7-a3f852cee9cb">KF6005/07</a></td> <td>Cebranopadol</td> <td>Chronic moderate to severe pain related to cancer</td> <td>CORAL - Cebranopadol versus morphine prolonged-release in patients with chronic moderate to severe pain related to cancer</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/08" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Moderate to severe chronic pain due to DPN" data-brief-title="Comparison of cebranopadol with placebo and with pregabalin" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="9302bd2f-c4cd-476a-a4f9-b8cc68839aef">KF6005/08</a></td> <td>Cebranopadol</td> <td>Moderate to severe chronic pain due to DPN</td> <td>Comparison of cebranopadol with placebo and with pregabalin</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6005/09" data-sponsor-substance-code="Cebranopadol" data-trial-indication="Chronic moderate to severe pain related to cancer" data-brief-title="CORAL XT - Open-label extension trial of the CORAL trial" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="a4a31033-1ba9-4887-80ef-959b755136f5">KF6005/09</a></td> <td>Cebranopadol</td> <td>Chronic moderate to severe pain related to cancer</td> <td>CORAL XT - Open-label extension trial of the CORAL trial</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8822-01" data-sponsor-substance-code="Chlormadinone Acetate 2,0mg; Ethynilestradiol 0,02mg" data-trial-indication="Contraception" data-brief-title="Bioavailability of Chlormadinone Acetate/Ethynilestradiol Tablets 2.0 mg/0,02 mg With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="68d9b63a-3b72-4499-a104-3cce8b12abda">HP8822-01</a></td> <td>Chlormadinone Acetate 2,0mg; Ethynilestradiol 0,02mg</td> <td>Contraception</td> <td>Bioavailability of Chlormadinone Acetate/Ethynilestradiol Tablets 2.0 mg/0,02 mg With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8810-02" data-sponsor-substance-code="Clotiazepam 5mg" data-trial-indication="Treatment of insomnia, anxiety" data-brief-title="Bioavailability of Clotiazepam 5 mg With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="e8381482-9487-42f9-916b-04d2fbea6619">HP8810-02</a></td> <td>Clotiazepam 5mg</td> <td>Treatment of insomnia, anxiety</td> <td>Bioavailability of Clotiazepam 5 mg With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8824-01" data-sponsor-substance-code="Desogestrel 0,75mg" data-trial-indication="Contraception" data-brief-title="Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="55c17bb8-f327-47b7-8c28-ce33d6b1ed68">HP8824-01</a></td> <td>Desogestrel 0,75mg</td> <td>Contraception</td> <td>Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8820-01" data-sponsor-substance-code="Dienogest 2,0mg" data-trial-indication="Contraception" data-brief-title="Bioavailability of Dienogest 2.0 mg With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="fa5dc123-e965-48e2-a0d4-30a27387d1cc">HP8820-01</a></td> <td>Dienogest 2,0mg</td> <td>Contraception</td> <td>Bioavailability of Dienogest 2.0 mg With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8811-01" data-sponsor-substance-code="Dienogest 2,0mg; Ethinylestradiol 0,03mg" data-trial-indication="Contraception" data-brief-title="Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="c4e48f67-c20d-43a5-a66b-cbf1e807647b">HP8811-01</a></td> <td>Dienogest 2,0mg; Ethinylestradiol 0,03mg</td> <td>Contraception</td> <td>Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8825-02" data-sponsor-substance-code="Duloxetine 60mg" data-trial-indication="Treatment of depression and anxiety" data-brief-title="Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="59927cee-770b-438d-9666-a202a51d1c70">HP8825-02</a></td> <td>Duloxetine 60mg</td> <td>Treatment of depression and anxiety</td> <td>Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8825-01" data-sponsor-substance-code="Duloxetine 60mg" data-trial-indication="Treatment of depression and anxiety" data-brief-title="Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="6cfb4998-08aa-4fa2-8c2d-63284b574192">HP8825-01</a></td> <td>Duloxetine 60mg</td> <td>Treatment of depression and anxiety</td> <td>Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP9906/06" data-sponsor-substance-code="Faxeladol" data-trial-indication="--" data-brief-title="A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="823e0e2d-315b-4c4d-8554-414cab67e077">HP9906/06</a></td> <td>Faxeladol</td> <td>--</td> <td>A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP9906/07" data-sponsor-substance-code="Faxeladol" data-trial-indication="--" data-brief-title="" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="d00c401f-35b4-4d52-9022-15400f12d933">HP9906/07</a></td> <td>Faxeladol</td> <td>--</td> <td></td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF9906/02" data-sponsor-substance-code="Faxeladol" data-trial-indication="Polyneuropathy" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="43ea2298-9aad-4656-810f-5bdbbce23687">KF9906/02</a></td> <td>Faxeladol</td> <td>Polyneuropathy</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF9906/03" data-sponsor-substance-code="Faxeladol" data-trial-indication="" data-brief-title="" data-trial-phase="2" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="30748f97-9d51-4d17-b980-6dd7c475549e">KF9906/03</a></td> <td>Faxeladol</td> <td></td> <td></td> <td>2</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6010-02" data-sponsor-substance-code="GRT6010" data-trial-indication="Bladder pain syndrome" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="71cd249c-b60c-43d2-9bf6-d886a5470ccc">KF6010-02</a></td> <td>GRT6010</td> <td>Bladder pain syndrome</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP6018-02" data-sponsor-substance-code="GRT6018" data-trial-indication="--" data-brief-title="--" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="7dbd8970-a68c-4d4d-b4e1-ec0acd165d0f">HP6018-02</a></td> <td>GRT6018</td> <td>--</td> <td>--</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF7019-01" data-sponsor-substance-code="GRT7019" data-trial-indication="Chronic pain due to knee osteoarthritis (OA)" data-brief-title="Lidocaine/diclofenac epolamine patch (GRT7019) Phase II proof-of-concept trial in subjects with chronic pain due to knee osteoarthritis" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="dc35904f-05b0-4174-87e7-b6ce4eb05362">KF7019-01</a></td> <td>GRT7019</td> <td>Chronic pain due to knee osteoarthritis (OA)</td> <td>Lidocaine/diclofenac epolamine patch (GRT7019) Phase II proof-of-concept trial in subjects with chronic pain due to knee osteoarthritis</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP7020-02" data-sponsor-substance-code="GRT7020" data-trial-indication="--" data-brief-title="Safety and tolerability of a dose escalation of neosaxitoxin alone and in combination with bupivacaine (with and without epinephrine) for brachial plexus blockade in healthy subjects" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="2756c240-b7e4-4a7c-82f2-2b48e9497a84">HP7020-02</a></td> <td>GRT7020</td> <td>--</td> <td>Safety and tolerability of a dose escalation of neosaxitoxin alone and in combination with bupivacaine (with and without epinephrine) for brachial plexus blockade in healthy subjects</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP7030-01" data-sponsor-substance-code="GRT7030" data-trial-indication="--" data-brief-title="A comparison of how much oxycodone is in the blood of healthy adults after taking different tablets on a full stomach and on an empty stomach" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="781a0be1-0369-48c9-a324-d344394bf7db">HP7030-01</a></td> <td>GRT7030</td> <td>--</td> <td>A comparison of how much oxycodone is in the blood of healthy adults after taking different tablets on a full stomach and on an empty stomach</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP7030-03" data-sponsor-substance-code="GRT7030" data-trial-indication="--" data-brief-title="A comparison of how likely it is that different tablets of oxycodone will be broken up and snorted by adults who sometimes take drugs for pleasure" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="ac5bb7cb-e56f-4852-af03-a75c3ee9a129">HP7030-03</a></td> <td>GRT7030</td> <td>--</td> <td>A comparison of how likely it is that different tablets of oxycodone will be broken up and snorted by adults who sometimes take drugs for pleasure</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8001-01; DCLF/TRMD-GRNN-01" data-sponsor-substance-code="GRT8001" data-trial-indication="--" data-brief-title="Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="039bc402-123d-41ea-8c7c-dd68c1d12b52">HP8001-01; DCLF/TRMD-GRNN-01</a></td> <td>GRT8001</td> <td>--</td> <td>Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF8001-01" data-sponsor-substance-code="GRT8001" data-trial-indication="Moderate to severe acute pain after third molar extraction" data-brief-title="Tramadol/diclofenac fixed-dose combination Phase III trial in acute pain after third molar extraction" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="efdcbd97-1881-4b7c-a086-be68f00a9846">KF8001-01</a></td> <td>GRT8001</td> <td>Moderate to severe acute pain after third molar extraction</td> <td>Tramadol/diclofenac fixed-dose combination Phase III trial in acute pain after third molar extraction</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8002-01" data-sponsor-substance-code="GRT8002" data-trial-indication="--" data-brief-title="Administration of Tramadol and Ketorolac Separately and Simultaneously to Assess a Potential Pharmacokinetic Interaction" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="7bd191c0-adca-46ce-88f0-1e4343c668ff">HP8002-01</a></td> <td>GRT8002</td> <td>--</td> <td>Administration of Tramadol and Ketorolac Separately and Simultaneously to Assess a Potential Pharmacokinetic Interaction</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8013-01; PRG-02-GRU/PK-PVR-01" data-sponsor-substance-code="GRT8013" data-trial-indication="--" data-brief-title="Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="241920a8-31ab-4934-84e8-e368b02bd3fc">HP8013-01; PRG-02-GRU/PK-PVR-01</a></td> <td>GRT8013</td> <td>--</td> <td>Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8814-01" data-sponsor-substance-code="levonorgestrel 0,15mg; ethinylestradiol 0,03mg" data-trial-indication="Contraception" data-brief-title="Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="dba0bfd1-6d0a-44e6-9963-53b4da6a3bec">HP8814-01</a></td> <td>levonorgestrel 0,15mg; ethinylestradiol 0,03mg</td> <td>Contraception</td> <td>Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8814-02" data-sponsor-substance-code="Levonorgestrol 0,10mg; Ethynilestradiol 0,02mg" data-trial-indication="Contraception" data-brief-title="Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product" data-trial-phase="1" data-trial-status="Completed" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="cae80c52-852d-4578-a9ae-778069d226c7">HP8814-02</a></td> <td>Levonorgestrol 0,10mg; Ethynilestradiol 0,02mg</td> <td>Contraception</td> <td>Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product</td> <td>1</td> <td>Completed</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF10004/03" data-sponsor-substance-code="Lidocaine" data-trial-indication="Postherpetic neuralgia and painful diabetic polyneuropathy" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="631d31d6-0c5a-4459-b754-2d744bc51f60">KF10004/03</a></td> <td>Lidocaine</td> <td>Postherpetic neuralgia and painful diabetic polyneuropathy</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF7013-01" data-sponsor-substance-code="Neridronic Acid" data-trial-indication="Treatment of pain associated with CRPS-I" data-brief-title="Efficacy and safety of intravenous neridronic acid in CRPS-I" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="ccea5805-1420-4398-8861-f9037d06dc07">KF7013-01</a></td> <td>Neridronic Acid</td> <td>Treatment of pain associated with CRPS-I</td> <td>Efficacy and safety of intravenous neridronic acid in CRPS-I</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF7013-03" data-sponsor-substance-code="Neridronic Acid" data-trial-indication="Complex Regional Pain Syndrome (CRPS)" data-brief-title="Safety of Intravenous Neridronic Acid in CRPS" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="6706c771-cebe-4ec3-a2f2-df4d006851df">KF7013-03</a></td> <td>Neridronic Acid</td> <td>Complex Regional Pain Syndrome (CRPS)</td> <td>Safety of Intravenous Neridronic Acid in CRPS</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5503-88" data-sponsor-substance-code="Tapentadol" data-trial-indication="--" data-brief-title="Comparison of blood concentrations of tapentadol from 4 prolonged release formulations (3 granule formulations and 1 tablet formulation) in healthy adult subjects" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="d51dcf16-6c0c-4d3a-894d-7ae0670be2b9">HP5503-88</a></td> <td>Tapentadol</td> <td>--</td> <td>Comparison of blood concentrations of tapentadol from 4 prolonged release formulations (3 granule formulations and 1 tablet formulation) in healthy adult subjects</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5503-93" data-sponsor-substance-code="Tapentadol" data-trial-indication="--" data-brief-title="A comparison of how much tapentadol is in the bloodstream of healthy men after taking different tablets on a full stomach" data-trial-phase="1" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="9f049761-16e2-4557-8e84-e42218eabc8d">HP5503-93</a></td> <td>Tapentadol</td> <td>--</td> <td>A comparison of how much tapentadol is in the bloodstream of healthy men after taking different tablets on a full stomach</td> <td>1</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/12" data-sponsor-substance-code="Tapentadol" data-trial-indication="Chronic pain in subjects for whom an opioid treatment is clinically appropriate" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="90b2e80a-2728-481e-afd3-ac9d83d2888a">KF5503/12</a></td> <td>Tapentadol</td> <td>Chronic pain in subjects for whom an opioid treatment is clinically appropriate</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/15" data-sponsor-substance-code="Tapentadol" data-trial-indication="Moderate to severe chronic malignant tumor-related pain" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="ac4a4f0c-06e2-4ef6-bdd4-86b1fc6526cf">KF5503/15</a></td> <td>Tapentadol</td> <td>Moderate to severe chronic malignant tumor-related pain</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/35" data-sponsor-substance-code="Tapentadol" data-trial-indication="Post-operative pain following abdominal hysterectomy" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="3b3a98db-c76e-4153-a830-617de5ad33e2">KF5503/35</a></td> <td>Tapentadol</td> <td>Post-operative pain following abdominal hysterectomy</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/37" data-sponsor-substance-code="Tapentadol" data-trial-indication="Post-operative pain following bunionectomy" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="7ad49e09-84ec-4c26-845d-c766db91e469">KF5503/37</a></td> <td>Tapentadol</td> <td>Post-operative pain following bunionectomy</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/42" data-sponsor-substance-code="Tapentadol" data-trial-indication="Chronic pain due to osteoarthritis of the knee" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="ba8c30a8-1796-4e4b-a159-c1f01a4d8c73">KF5503/42</a></td> <td>Tapentadol</td> <td>Chronic pain due to osteoarthritis of the knee</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/44" data-sponsor-substance-code="Tapentadol" data-trial-indication="Chronic nociceptive, mixed or neuropathic low back pain" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="d4c867d9-da81-4812-b3c6-a327c16c6db3">KF5503/44</a></td> <td>Tapentadol</td> <td>Chronic nociceptive, mixed or neuropathic low back pain</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/52" data-sponsor-substance-code="Tapentadol" data-trial-indication="Chronic malignant tumor-related pain" data-brief-title="Tapentadol in chronic malignant tumor related pain" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="ddd72692-4c60-42a1-9589-eb89aa5d5a1e">KF5503/52</a></td> <td>Tapentadol</td> <td>Chronic malignant tumor-related pain</td> <td>Tapentadol in chronic malignant tumor related pain</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/53" data-sponsor-substance-code="Tapentadol" data-trial-indication="Psychomotor performance as a surrogate parameter for driving ability in subjects with chronic low back pain or osteoarthritis of the knee" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="37709768-c1af-4817-a46b-01386bf6717e">KF5503/53</a></td> <td>Tapentadol</td> <td>Psychomotor performance as a surrogate parameter for driving ability in subjects with chronic low back pain or osteoarthritis of the knee</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/58" data-sponsor-substance-code="Tapentadol" data-trial-indication="Severe chronic low back pain with a neuropathic pain component" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="93928d4c-48c3-45d5-8f38-a894c779744b">KF5503/58</a></td> <td>Tapentadol</td> <td>Severe chronic low back pain with a neuropathic pain component</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/60" data-sponsor-substance-code="Tapentadol" data-trial-indication="Severe chronic low back pain with a neuropathic pain component" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="e29b3077-d642-4cf7-ad05-192718640f1e">KF5503/60</a></td> <td>Tapentadol</td> <td>Severe chronic low back pain with a neuropathic pain component</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/62" data-sponsor-substance-code="Tapentadol" data-trial-indication="Treatment of acute pain following bunionectomy" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="0bd063de-8398-4d3b-9442-bb489d8020de">KF5503/62</a></td> <td>Tapentadol</td> <td>Treatment of acute pain following bunionectomy</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/65" data-sponsor-substance-code="Tapentadol" data-trial-indication="Treatment of acute pain following bunionectomy" data-brief-title="A study to look at Tapentadol Oral Solution in Children and Adolescents in pain after Surgery" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="20b8633e-5c19-4def-b163-8734a50c0fcd">KF5503/65</a></td> <td>Tapentadol</td> <td>Treatment of acute pain following bunionectomy</td> <td>A study to look at Tapentadol Oral Solution in Children and Adolescents in pain after Surgery</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503-66" data-sponsor-substance-code="Tapentadol" data-trial-indication="--" data-brief-title="A study to look at Tapentadol Tablets in Children and Adolescents in pain" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="024f72f1-6d82-460e-802f-900ee506be87">KF5503-66</a></td> <td>Tapentadol</td> <td>--</td> <td>A study to look at Tapentadol Tablets in Children and Adolescents in pain</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/68" data-sponsor-substance-code="Tapentadol" data-trial-indication="Post-surgical pain" data-brief-title="--" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="963b3222-413d-4f09-bd12-cfec58610f25">KF5503/68</a></td> <td>Tapentadol</td> <td>Post-surgical pain</td> <td>--</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503-73" data-sponsor-substance-code="Tapentadol" data-trial-indication="Moderate to severe acute post-operative pain" data-brief-title="Use of intravenous tapentadol solution for injection for pain after surgery in children from newborn to less than 2 years old, including preterm babies" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="a2c58661-53a2-4d01-95ee-cd2ddf337a4c">KF5503-73</a></td> <td>Tapentadol</td> <td>Moderate to severe acute post-operative pain</td> <td>Use of intravenous tapentadol solution for injection for pain after surgery in children from newborn to less than 2 years old, including preterm babies</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503-75" data-sponsor-substance-code="Tapentadol" data-trial-indication="Moderate to severe acute pain" data-brief-title="A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term pain" data-trial-phase="2" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="c67cca70-f2f8-45c6-97cd-a7a790bfdd1b">KF5503-75</a></td> <td>Tapentadol</td> <td>Moderate to severe acute pain</td> <td>A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term pain</td> <td>2</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="FO-PK 401" data-sponsor-substance-code="Tramadol" data-trial-indication="Children undergoing elective limb surgery or urogenital surgery" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="e2176700-a5b1-4f15-bfc8-60880b80ce30">FO-PK 401</a></td> <td>Tramadol</td> <td>Children undergoing elective limb surgery or urogenital surgery</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="TRA-RSA-2" data-sponsor-substance-code="Tramadol" data-trial-indication="Children undergoing multiple dental extractions under general anaesthesia" data-brief-title="--" data-trial-phase="3" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="80887cad-2470-4581-a0cf-75f043ca621c">TRA-RSA-2</a></td> <td>Tramadol</td> <td>Children undergoing multiple dental extractions under general anaesthesia</td> <td>--</td> <td>3</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="WIS-AL-TRA86-04-95" data-sponsor-substance-code="Tramadol" data-trial-indication="Post-operative pain after abdominal surgery" data-brief-title="Open clinical study on the analgesic efficacy of tramadol (TRAMAL) in children with post-operative pain after abdominal surgery" data-trial-phase="4" data-trial-status="Completed" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="6a5180d6-4422-44ae-a2ac-4bf58f7e69df">WIS-AL-TRA86-04-95</a></td> <td>Tramadol</td> <td>Post-operative pain after abdominal surgery</td> <td>Open clinical study on the analgesic efficacy of tramadol (TRAMAL) in children with post-operative pain after abdominal surgery</td> <td>4</td> <td>Completed</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF10004/08" data-sponsor-substance-code="5% Lidocaine medicated plaster" data-trial-indication="Localized chronic postoperative neuropathic pain (PoNP)" data-brief-title="--" data-trial-phase="2" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="4a666dcf-5b31-46bc-9718-76a9d47d7621">KF10004/08</a></td> <td>5% Lidocaine medicated plaster</td> <td>Localized chronic postoperative neuropathic pain (PoNP)</td> <td>--</td> <td>2</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5303/10" data-sponsor-substance-code="Burprenorphine" data-trial-indication="--" data-brief-title="Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations" data-trial-phase="1" data-trial-status="Terminated" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="e1ee3f3a-aa0c-49e8-ad4b-5c8c6526c0fe">HP5303/10</a></td> <td>Burprenorphine</td> <td>--</td> <td>Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations</td> <td>1</td> <td>Terminated</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5303/11" data-sponsor-substance-code="Burprenorphine" data-trial-indication="--" data-brief-title="--" data-trial-phase="1" data-trial-status="Terminated" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="34cfa822-69d4-4d9a-b97c-2da8c00c8253">HP5303/11</a></td> <td>Burprenorphine</td> <td>--</td> <td>--</td> <td>1</td> <td>Terminated</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5303/12" data-sponsor-substance-code="Burprenorphine" data-trial-indication="--" data-brief-title="--" data-trial-phase="1" data-trial-status="Terminated" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="80307490-ae3f-481f-825a-11279d33f180">HP5303/12</a></td> <td>Burprenorphine</td> <td>--</td> <td>--</td> <td>1</td> <td>Terminated</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP5303/13" data-sponsor-substance-code="Burprenorphine" data-trial-indication="--" data-brief-title="--" data-trial-phase="1" data-trial-status="Terminated" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="a15ceacb-7335-4b50-a00e-1d910d981a0d">HP5303/13</a></td> <td>Burprenorphine</td> <td>--</td> <td>--</td> <td>1</td> <td>Terminated</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF6010/01" data-sponsor-substance-code="GRT6010" data-trial-indication="Peripheral neuropathic pain" data-brief-title="--" data-trial-phase="2" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="1b6283ac-89b7-4889-b1ea-281c692aa92d">KF6010/01</a></td> <td>GRT6010</td> <td>Peripheral neuropathic pain</td> <td>--</td> <td>2</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP6015-01" data-sponsor-substance-code="GRT6015" data-trial-indication="--" data-brief-title="Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single doses of GRT6015 in healthy men" data-trial-phase="1" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="11132a66-823d-477c-9697-407288731099">HP6015-01</a></td> <td>GRT6015</td> <td>--</td> <td>Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single doses of GRT6015 in healthy men</td> <td>1</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF7021-04" data-sponsor-substance-code="GRT7021" data-trial-indication="Closure of Surgical Incisions and Lacerations" data-brief-title="A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced" data-trial-phase="Pivotal" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="b54669e8-e1a5-461c-9fe2-38bbb09a6f2a">KF7021-04</a></td> <td>GRT7021</td> <td>Closure of Surgical Incisions and Lacerations</td> <td>A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced</td> <td>Pivotal</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP7030-02" data-sponsor-substance-code="GRT7030" data-trial-indication="--" data-brief-title="A comparison of how much oxycodone is in the blood of healthy adults after taking different amounts of different tablets on an empty stomach" data-trial-phase="1" data-trial-status="Terminated" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="e6af65e4-6e9c-4cb5-ad4b-ccad4cc51d73">HP7030-02</a></td> <td>GRT7030</td> <td>--</td> <td>A comparison of how much oxycodone is in the blood of healthy adults after taking different amounts of different tablets on an empty stomach</td> <td>1</td> <td>Terminated</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF7013-02" data-sponsor-substance-code="Neridronic Acid" data-trial-indication="Complex Regional Pain Syndrome (CRPS)" data-brief-title="Efficacy and safety of intravenous neridronic acid in CRPS" data-trial-phase="3" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="2c18b982-3ebb-4ea0-82d8-d9ef21fe8dd5">KF7013-02</a></td> <td>Neridronic Acid</td> <td>Complex Regional Pain Syndrome (CRPS)</td> <td>Efficacy and safety of intravenous neridronic acid in CRPS</td> <td>3</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF7013-04" data-sponsor-substance-code="Neridronic Acid" data-trial-indication="Complex Regional Pain Syndrome (CRPS)" data-brief-title="Efficacy and safety of intravenous neridronic acid in CRPS" data-trial-phase="3" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="45001c9b-ce38-4793-89c4-30043266d7c1">KF7013-04</a></td> <td>Neridronic Acid</td> <td>Complex Regional Pain Syndrome (CRPS)</td> <td>Efficacy and safety of intravenous neridronic acid in CRPS</td> <td>3</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/16" data-sponsor-substance-code="Tapentadol" data-trial-indication="Moderate to severe chronic malignant tumor-related pain" data-brief-title="--" data-trial-phase="3" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="1b9be24b-c74e-4ea0-84de-17b07c6cf2a7">KF5503/16</a></td> <td>Tapentadol</td> <td>Moderate to severe chronic malignant tumor-related pain</td> <td>--</td> <td>3</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/43" data-sponsor-substance-code="Tapentadol" data-trial-indication="Chronic pain due to osteoarthritis of the knee" data-brief-title="--" data-trial-phase="3" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="31af82a6-6217-46d5-ae70-d922df060e2a">KF5503/43</a></td> <td>Tapentadol</td> <td>Chronic pain due to osteoarthritis of the knee</td> <td>--</td> <td>3</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503/45" data-sponsor-substance-code="Tapentadol" data-trial-indication="Chronic nociceptive, mixed or neuropathic low back pain" data-brief-title="--" data-trial-phase="3" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="ff1a1913-fe8c-47fa-9e9b-6a73ef685bb5">KF5503/45</a></td> <td>Tapentadol</td> <td>Chronic nociceptive, mixed or neuropathic low back pain</td> <td>--</td> <td>3</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="KF5503-72" data-sponsor-substance-code="Tapentadol" data-trial-indication="Moderate to severe acute post-operative pain" data-brief-title="Use of tapentadol oral solution for pain after surgery in children from newborn to less than 2 years old" data-trial-phase="2" data-trial-status="Terminated" data-results-posted="Yes" style="display: none;"> <td><a data-clinical-trial-item-id="429684fd-4dbe-4e8a-9f95-4a3cfa566c21">KF5503-72</a></td> <td>Tapentadol</td> <td>Moderate to severe acute post-operative pain</td> <td>Use of tapentadol oral solution for pain after surgery in children from newborn to less than 2 years old</td> <td>2</td> <td>Terminated</td> <td>Yes</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP7014-01" data-sponsor-substance-code="GRT7014" data-trial-indication="--" data-brief-title="A comparison of plasma concentrations of hydrocodone and acetaminophen after administration of a new and a marketed tablet formulation under fasted and fed conditions in healthy adults" data-trial-phase="1" data-trial-status="Withdrawn" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="1ac700d9-98ac-44f7-8e6a-1ed06d2e20af">HP7014-01</a></td> <td>GRT7014</td> <td>--</td> <td>A comparison of plasma concentrations of hydrocodone and acetaminophen after administration of a new and a marketed tablet formulation under fasted and fed conditions in healthy adults</td> <td>1</td> <td>Withdrawn</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP7014-02" data-sponsor-substance-code="GRT7014" data-trial-indication="--" data-brief-title="A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults" data-trial-phase="1" data-trial-status="Withdrawn" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="262191cf-11e9-4a29-a4dc-2f70c6024d2f">HP7014-02</a></td> <td>GRT7014</td> <td>--</td> <td>A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults</td> <td>1</td> <td>Withdrawn</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8010-01; ESTNMG-04-GRU" data-sponsor-substance-code="GRT8010" data-trial-indication="--" data-brief-title="Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate" data-trial-phase="1" data-trial-status="Withdrawn" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="3c5276f9-173f-4119-9f28-e0e9d9a44021">HP8010-01; ESTNMG-04-GRU</a></td> <td>GRT8010</td> <td>--</td> <td>Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate</td> <td>1</td> <td>Withdrawn</td> <td>No</td> </tr> <tr class="clinicalTrialRow" data-clinical-trial-id="HP8012-01" data-sponsor-substance-code="GRT8012" data-trial-indication="--" data-brief-title="A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions" data-trial-phase="1" data-trial-status="Withdrawn" data-results-posted="No" style="display: none;"> <td><a data-clinical-trial-item-id="18c29425-dce0-4b89-b264-f94c0f904f5c">HP8012-01</a></td> <td>GRT8012</td> <td>--</td> <td>A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions</td> <td>1</td> <td>Withdrawn</td> <td>No</td> </tr> </tbody> </table> <div class="clinicalTrialsPagerNoDetails"> <div class="clinicalTrialsPagerContainer"> <div class="row"> <div class="columns small-12"> <div class="clinicalTrialsPager columns small-12" data-count="89"> <a class="clinicalTrialsPagerPreviousButton button" role="button" style="display: none;"> <span class="icon-left"></span> <span class="underline">Previous [10]</span> </a> <a class="clinicalTrialsPagerNextButton button" role="button"> <span class="underline">Next [<span class="clinicalTrialsPagerNextText">79</span>]</span> <span class="icon-right"></span> </a> </div> </div> </div> </div> </div> <div class="backToOverviewContainer row" style="display: none;"> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <a class="backToClinicalTrialOverview button"><span class="icon-left backButton"></span> <span class="button__elipsis">...</span> Back to overview</a><br /><br /> </div> <div class="columns small-2"></div> </div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="e876e6ac-12ad-41d0-b243-92081a8b45be" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong></strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td></td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td></td> </tr> <tr> <td><strong>Trial title:</strong></td> <td></td> </tr> <tr> <td><strong>Brief title:</strong></td> <td></td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td></td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td></td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td></td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td></td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td></td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="31647c0e-73c5-4684-8fc3-db8f686e9078" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF10004/01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Versatis®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>5% Lidocaine medicated plaster</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A double-blind, multicentre, multiple-dose, enriched enrolment, randomized-withdrawal, parallel-group phase III study with Lido-Patch and corresponding placebo plaster in patients suffering from postherpetic neuralgia (PHN)</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td></td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Postherpetic neuralgia </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/29/2003</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>6/30/2004</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03745404?term=NCT03745404&rank=1" class="" target="_blank" rel="noopener">NCT03745404</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="a105ddb1-d77b-41d7-bbd8-f055322c871b" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF10004/02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Versatis®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>5% Lidocaine medicated plaster</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An open-label, multicenter, multiple-dose, Phase III study with Lidocaine 5% medicated plaster in patients suffering from postherpetic neuralgia</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td></td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Postherpetic neuralgia </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>7/16/2003</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/12/2005</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03765697?term=NCT03765697&rank=1" class="" target="_blank" rel="noopener">NCT03765697</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="2f5650cb-0f21-42ad-8beb-6d5affa059c7" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF10004/10</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Versatis®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>5% Lidocaine medicated plaster</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Localized chronic post-operative neuropathic pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/23/2012</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>6/21/2016</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1143-2130</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01752322?term=NCT01752322&rank=1" class="" target="_blank" rel="noopener">NCT01752322</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-000347-28" class="" target="_blank" rel="noopener">2012-000347-28</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf10004-10-lay-summary-english-spanish.pdf?rev=a18cacc49a204d25aa58226efa869669" target="_blank" rel="noopener">kf10004-10 lay summary</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ec5d6094-6d27-45e0-bb5f-33caf049d69e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>EN3324-201</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Axomadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A Phase IIB, Randomized, Double-blind, Two-Arm, Multi-Center, Placebo-Controlled Study to Assess the Efficacy and Safety of EN3324 (Axomadol) in Subjects with Moderate to Severe Chronic Low Back Pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe chronic low back pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>12/11/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>5/9/2011</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT01043263 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="cafb44bf-02a3-4b07-9805-7f94704a0e97" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP0151Y/09</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Axomadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A Phase-I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Oral Doses of GRT0151Y in Healthy Male and Female Subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>12/30/2004</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/26/2005</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03761407?term=NCT03761407&rank=1" class="" target="_blank" rel="noopener">NCT03761407</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="bddb4f05-e7ed-4df8-99c6-77f4ec97066d" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP0151Y/10</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Axomadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An Ascending Single-Dose Safety, Tolerability and Exposure Study to Explore the Maximum Tolerated Dose of GRT0151Y in Healthy Adult Non-dependent Recreational Opiate Users</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/20/2006</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/2/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03765658?term=NCT03765658&rank=1" class="" target="_blank" rel="noopener">NCT03765658</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="d002f4cd-fd59-440e-8872-ee4fd66d0d32" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP0151Y/13</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Axomadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A Single-Dose, Randomized, Double Blind, Placebo and Active Controlled Cross-Over Study to Evaluate the Abuse Potential of Three Doses of GRT0151Y in Adult Non-dependent Recreational Opiate Users</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/21/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/25/2007</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03768024?term=NCT03768024&rank=1" class="" target="_blank" rel="noopener">NCT03768024</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="bf2cd48c-33d4-424c-8829-46565341df39" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF0151Y/06</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Axomadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, multi-center, double-blind, parallel-group, multiple-dose study assessing the analgesic efficacy and safety of 3 different doses of GRT0151Y compared to placebo and an active comparator in adults following tonsillectomy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Postoperative pain following tonsillectomy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>8/12/2005</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/17/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-001656-21+" class="" target="_blank" rel="noopener">2005-001656-21</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ed0d5155-d07c-48f6-bf01-ceff7ada9b18" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF0151Y/07</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Axomadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, multi-center, double blind, parallel-group study assessing the analgesic efficacy and safety of different dosages of GRT0151Y BID compared to active comparator BID and placebo BID in subjects with chronic knee-joint osteoarthritis</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic knee-joint osteoarthritis </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/22/2005</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/11/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=+2005-003360-26+" class="" target="_blank" rel="noopener">2005-003360-26</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="f9133c4a-005d-4358-a9b1-875e89daf12e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5303/04</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Investigation of the Pharmacokinetics of a Transtec&reg; 35 &mu;g/h Transdermal Patch Application for 96 Hours and a Patch Application for 72 Hours in an Open, Randomised, Single Application, Two-period Crossover, Phase I Study in 30 Healthy Male Volunteers</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/5/2004</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>5/26/2004</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03770234?term=NCT03770234&rank=1" class="" target="_blank" rel="noopener">NCT03770234</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="aaf9c08e-cd80-42f8-b467-1b3ec10c0d7b" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5303/05</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Pilot study to investigate the pharmacokinetic characteristics of two buprenorphine transdermal patch formulations as compared to a reference patch</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Clinical Pilot Study in Healthy Men to Characterize the Uptake of Buprenorphine Into and Its Elimination From the Body After Topical Application of Two New Forms of a Skin Patch in Comparison to a Reference Patch</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/7/2005</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/14/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03785613?term=NCT03785613&rank=1" class="" target="_blank" rel="noopener">NCT03785613</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="61362129-25cd-4d17-ae0c-0fc205cc416e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5303/01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Transtec®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, 2-arm, parallel group study assessing safety and efficacy of titrated transdermal buprenorphine in patients with moderate to severe chronic non-malignant pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe chronic pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/5/2006</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/3/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005365-11" class="" target="_blank" rel="noopener">2005-005365-11</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ecb450ad-c207-4a6a-993e-977fb19fc4e4" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>GRT-PK-07</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A non-randomized, single-dose, open-label, pharmacokinetic study of cebranopadol in patients with impaired renal function and subjects with normal renal function</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/20/2013</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/17/2014</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03882762?term=grt-pk-07&rank=1" class="" target="_blank" rel="noopener">NCT03882762</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="18cefee5-59e9-45b9-aed6-d1e3195655b9" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP6005/10</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A single-dose, nested-randomized, double-blind, double-dummy, placebo- and active-controlled crossover trial to evaluate the abuse potential of 3 doses of GRT6005 in adult non-dependent recreational opioid users</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Trial to Evaluate the Abuse Potential of 3 Doses of GRT6005 in Adult Non-dependent Recreational Opioid Users</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/15/2013</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/8/2014</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03757559?term=NCT03757559&rank=1" class="" target="_blank" rel="noopener">NCT03757559</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td></td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="b40264c6-4bf2-4601-9458-c4b449a03714" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, Phase IIa trial evaluating the safety and efficacy of a new centrally acting analgesic in subjects with moderate to severe pain following bunionectomy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe pain following bunionectomy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>3/19/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/13/2009</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00872885?term=NCT00872885&rank=1" class="" target="_blank" rel="noopener">NCT00872885</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="c064263a-97aa-4443-8737-97118dcdc31e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized Phase IIa trial evaluating the safety and efficacy of a new centrally acting analgesic in subjects with pain due to diabetic polyneuropathy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Pain due to diabetic polyneuropathy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/15/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>5/25/2010</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00878293?term=NCT00878293&rank=1" class="" target="_blank" rel="noopener">NCT00878293</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004794-18" class="" target="_blank" rel="noopener">2008-004794-18</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="8a87a213-3fec-414d-8f8d-996ae1419650" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/03</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized 4-week Phase IIa trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic, in subjects with moderate to severe pain due to osteoarthritis (OA) of the knee</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe pain due to OA of the knee </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/25/2011</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/15/2011</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01357837?term=NCT01357837&rank=1" class="" target="_blank" rel="noopener">NCT01357837</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022556-23" class="" target="_blank" rel="noopener">2010-022556-23</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="a2a44a5e-12d0-4bb1-b9bd-9c140e747812" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/04</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized 4-week Phase IIa trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic, in subjects with pain due to diabetic polyneuropathy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe pain due to diabetic polyneuropathy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/4/2011</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/5/2012</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01347671?term=NCT01347671&rank=1" class="" target="_blank" rel="noopener">NCT01347671</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022557-42" class="" target="_blank" rel="noopener">2010-022557-42</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="5472e711-acc3-410a-9a11-633d23d86482" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/06</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Efficacy, safety, and tolerability of GRT6005 in subjects with moderate to severe chronic low back pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Efficacy and safety of GRT6005 in patients with chronic low back pain</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Low back pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/30/2012</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/10/2014</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01725087?term=NCT01725087&rank=1" class="" target="_blank" rel="noopener">NCT01725087</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001920-36" class="" target="_blank" rel="noopener">2012-001920-36</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="20f6cedd-8bb1-420a-9ee7-a3f852cee9cb" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/07</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Efficacy, safety, and tolerability of oral cebranopadol versus morphine sulfate PR in subjects with chronic moderate to severe pain related to cancer</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>CORAL - Cebranopadol versus morphine prolonged-release in patients with chronic moderate to severe pain related to cancer</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic moderate to severe pain related to cancer </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=30365202" class="" target="_blank" rel="noopener">30365202</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/29/2013</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/16/2015</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1143-1808</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01964378?term=NCT01964378&rank=1" class="" target="_blank" rel="noopener">NCT01964378</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-001316-35" class="" target="_blank" rel="noopener">2012-001316-35</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="9302bd2f-c4cd-476a-a4f9-b8cc68839aef" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/08</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Efficacy, safety and tolerability of multiple doses of oral cebranopadol in subjects with moderate to severe chronic pain due to diabetic peripheral neuropathy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Comparison of cebranopadol with placebo and with pregabalin</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe chronic pain due to DPN </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/27/2013</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/28/2015</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1151-4331</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01939366?term=NCT01939366&rank=1" class="" target="_blank" rel="noopener">NCT01939366</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-000473-68" class="" target="_blank" rel="noopener">2013-000473-68</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="a4a31033-1ba9-4887-80ef-959b755136f5" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6005/09</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Cebranopadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An open-label, multi-site trial to describe the safety and tolerability of oral cebranopadol administered for 26 weeks in subjects with cancer-related pain who have completed treatment in the KF6005/07 trial</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>CORAL XT - Open-label extension trial of the CORAL trial</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic moderate to severe pain related to cancer </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>12/18/2013</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>5/3/2016</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1144-0778</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT02031432?term=NCT02031432&rank=1" class="" target="_blank" rel="noopener">NCT02031432</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-001877-26" class="" target="_blank" rel="noopener">2013-001877-26</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="68d9b63a-3b72-4499-a104-3cce8b12abda" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8822-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Serenata 20</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Chlormadinone Acetate 2,0mg; Ethynilestradiol 0,02mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossover bioequivalent trial of an oral formulation of Chlormadinone / Ethinylestradiol® coated tablets of 2.00 mg / 0.02 mg, prepared by Laboratorios Andrómaco SA, with respect to the Evafem 20® formulation, 2.00 mg / 0.02 mg coated tablets, considered as comparison reference, manufactured by Gedeon Richter Plc. For Grünenthal Chilena Ltda., In 38 healthy volunteers after one dose of two tablets.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Chlormadinone Acetate/Ethynilestradiol Tablets 2.0 mg/0,02 mg With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Contraception </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/12/2021</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/2/2021</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04713904 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="e8381482-9487-42f9-916b-04d2fbea6619" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8810-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Rize 5mg</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Clotiazepam 5mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossed bioequivalent trial of an oral formulation of Clotiazepam prepared by Tecnandina S.A. Ecuador in the pharmaceutical form tablets 5 mg coated, with respect to the Rize® formulation, tablets 5 mg coated, considered as a comparison reference, manufactured by Mitsubishi Tanabe Pharma Corporation, Japan in 30 healthy volunteers after a single dose of one tablet.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Clotiazepam 5 mg With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Treatment of insomnia, anxiety </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>2/26/2020</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/20/2020</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04440423 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="55c17bb8-f327-47b7-8c28-ce33d6b1ed68" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8824-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Lactafem</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Desogestrel 0,75mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, double-blind and crossover bioequivalent trial of an oral formulation of Desogestrel elaborated by Laboratorios Andr&oacute;maco SA, in the pharmaceutical form, coated tablets of 75 mcg, with respect to the formulation Cerazette&reg;, coated tablets 0.075 mg, considered as a comparison reference, manufactured by Merck Sharp &amp; Dohme., in 30 healthy volunteers after one dose of 2 tablets.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Desogestrel 0.075 mg Tablets With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Contraception </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>12/27/2019</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/28/2020</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04422028 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="fa5dc123-e965-48e2-a0d4-30a27387d1cc" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8820-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Alondra</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Dienogest 2,0mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossover bioequivalence trial of an oral formulation of Dienogest 2.00 mg coated tablets prepared by Laboratorios Andrómaco SA, with respect to the Visannette® formulation, 2.00 tablets. mg, considered as a reference for comparison, manufactured by Bayer SA, in 30 healthy volunteers after a single dose of one tablet.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Dienogest 2.0 mg With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Contraception </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/27/2019</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/24/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04230083 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="c4e48f67-c20d-43a5-a66b-cbf1e807647b" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8811-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Tinelle & Gianda CD</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Dienogest 2,0mg; Ethinylestradiol 0,03mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossover bioequivalent trials of an oral formulation of Dienogest / Ethinylestradiol elaborated by Laboratorios Andrómaco, in the pharmaceutical form of coated tablets of 2.00 mg / 0.03 mg, with respect to the Valette® formulation, 2.00 mg / 0.03 mg coated tablets, considered as a reference for comparison, manufactured by Jenepharm, Germany, in 30 healthy volunteers after one dose of 2 tablets.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Dienogest and Ethinyl Estradiol Tablets 2.0 mg/0.03 mg With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Contraception </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>2/22/2020</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/10/2020</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04193852 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="59927cee-770b-438d-9666-a202a51d1c70" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8825-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Nitexol 60 mg_Fast</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Duloxetine 60mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossed bioequivalent trial of an oral formulation of Duloxetine Hydrochloride 60 mg enteric-coated granule capsules made by Laboratorios Andrómaco S.A., regarding the Cymbalta® formulation, capsules with enteric-coated granules of 60 mg, considered to be comparison reference, manufactured by Lilly del Caribe for Ely Lilly Inter-America Inc. and CIA. Ltda., In 36 healthy volunteers after a single dose of 1 tablet under fasting conditions.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Treatment of depression and anxiety </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/18/2021</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/9/2021</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04723238 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="6cfb4998-08aa-4fa2-8c2d-63284b574192" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8825-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Nitexol 60 mg_Fed</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Duloxetine 60mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossed bioequivalent trial of an oral formulation of Duloxetine Hydrochloride 60 mg enteric-coated granule capsules made by Laboratorios Andrómaco S.A., regarding the Cymbalta® formulation, capsules with enteric-coated granules of 60 mg, considered to be comparison reference, manufactured by Lilly del Caribe for Ely Lilly Inter-America Inc. and CIA. Ltda., In 36 healthy volunteers after a single dose of 1 tablet under feeding conditions.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Treatment of depression and anxiety </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>2/27/2021</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/16/2021</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04751318 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="823e0e2d-315b-4c4d-8554-414cab67e077" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP9906/06</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Faxeladol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Phase I, Single-center Study to Explore the Relative Bioavailability and the Effect of Food on the Bioavailability of Prolonged Release Tablets Compared to Immediate Release Capsules Each Containing 60 mg of GRTA9906 in 20 Healthy Female Volunteers</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/22/2003</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/11/2003</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03765801?term=NCT03765801&rank=1" class="" target="_blank" rel="noopener">NCT03765801</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="d00c401f-35b4-4d52-9022-15400f12d933" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP9906/07</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Faxeladol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A phase I, single center, multiple dose, dose escalation study (within dose-group randomized, double-blind, placebo-controlled, 2-way cross-over) to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GRT9906 prolonged release tablets in healthy male and female subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td></td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/15/2004</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/23/2005</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03776110?term=NCT03776110&rank=1" class="" target="_blank" rel="noopener">NCT03776110</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="43ea2298-9aad-4656-810f-5bdbbce23687" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF9906/02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Faxeladol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Crossover multiple-dose trial assessing the analgesic efficacy and safety of oral GRT9906 PR compared with active comparator and placebo in subjects with painful polyneuropathy of mixed origin</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Polyneuropathy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/8/2005</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/9/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=+2005-001404-40+" class="" target="_blank" rel="noopener">2005-001404-40</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="30748f97-9d51-4d17-b980-6dd7c475549e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF9906/03</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Faxeladol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Crossover multiple-dose trial assessing the analgesic efficacy and safety of oral GRT9906 compared to placebo in subjects with primary fibromyalgia syndrome</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td></td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/19/2005</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/20/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03783910?term=NCT03783910&rank=1" class="" target="_blank" rel="noopener">NCT03783910</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="71cd249c-b60c-43d2-9bf6-d886a5470ccc" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6010-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT6010</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Exploratory, randomized, double-blind, placebo-controlled evaluation of efficacy, tolerability, and safety of intravesical instillation of GRT6010 compared to placebo in subjects with bladder pain syndrome</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Bladder pain syndrome </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>7/26/2017</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>5/2/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1188-0214</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-003940-35" class="" target="_blank" rel="noopener">2016-003940-35</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf6010-02-lay-summary-german.pdf?rev=577faf6c940f41e99d56ecc2d3bb8aa5&sc_lang=en" target="_blank" rel="noopener">kf6010-02-lay-summary-german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf6010-02-lay-summary-polish.pdf?rev=278a2925388543cbb39372d140248ab7&sc_lang=en" target="_blank" rel="noopener">kf6010-02-lay-summary-polish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf6010-02-expert-summary.pdf?rev=8874392e996344efb97c34b59b06ddb5" target="_blank" rel="noopener">kf6010-02-expert-summary</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="7dbd8970-a68c-4d4d-b4e1-ec0acd165d0f" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP6018-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT6018</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A Phase I, single-site, randomized, double-blind, double-dummy, placebo- and active reference-controlled, crossover trial to assess the effects of single oral doses of GRT6018 on laser-evoked potentials in healthy male subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/24/2021</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>11/22/2021</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U111-1267-7043</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2021-002305-95 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp6018-02_plain-language-summary.pdf?rev=1cc9c3ca188545109a97e16d4c828474" target="_blank" rel="noopener">GRT 6018 lay summary English</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp6018-02_plain-language-summary_german.pdf?rev=f32a73fc8cb04176ab17f90645fbbea3" target="_blank" rel="noopener">GRT 6018 lay summary German</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="dc35904f-05b0-4174-87e7-b6ce4eb05362" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF7019-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7019</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An exploratory, randomized, double-blind, double-dummy, placebo- and active-controlled Phase II trial to evaluate the efficacy and safety of a topical application of GRT7019 in subjects with chronic pain due to knee osteoarthritis</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Lidocaine/diclofenac epolamine patch (GRT7019) Phase II proof-of-concept trial in subjects with chronic pain due to knee osteoarthritis</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic pain due to knee osteoarthritis (OA) </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/12/2017</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/17/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1184-3912</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=kf7019-01" class="" target="_blank" rel="noopener">2016‐002611‐18</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH </td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7019-01-lay-summary-english.pdf?rev=1fb2a0e93cb44e43891073e58d445eed" target="_blank" rel="noopener">kf7019-01-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7019-01-lay-summary-german.pdf?rev=968602dc5046486db5920de026a106a7" target="_blank" rel="noopener">kf7019-01-lay-summary-german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7019-01-lay-summary-spanish.pdf?rev=b3530c8385fb4e4593c806d12f6bad02" target="_blank" rel="noopener">kf7019-01-lay-summary-spanish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7019-01-lay-summary-polish.pdf?rev=5a2a8960fa8d4d309fbb56a0de1819fd" target="_blank" rel="noopener">kf7019-01-lay-summary-polish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf7019-01-expert-summary.pdf?rev=db32d839920340179bdef4aad00b38c2" target="_blank" rel="noopener">kf7019-01-expert-summary</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="2756c240-b7e4-4a7c-82f2-2b48e9497a84" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP7020-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>GRT7020</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7020</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An exploratory Phase I randomized, single-site, double-blind, active-controlled, parallel-group, single-administration, dose-escalation trial to investigate the safety and tolerability of neosaxitoxin alone and in combination with bupivacaine (with and without epinephrine), in perineural administrations for brachial plexus blockade in healthy subjects.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Safety and tolerability of a dose escalation of neosaxitoxin alone and in combination with bupivacaine (with and without epinephrine) for brachial plexus blockade in healthy subjects</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/30/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/21/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1189-1950</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03399435?term=NCT03399435&rank=1" class="" target="_blank" rel="noopener">NCT03399435</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search;jsessionid=U91HGeiMS3aRFeKP1_fMLDlZhkMu4mOTrc33GTn71agYZUtKqGhf!-329124871" class="" target="_blank" rel="noopener">2016-003958-33</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7020-02-lay-summary.pdf?rev=e4dcb6baa6f642ed8b74222b82f36d6b" target="_blank" rel="noopener">hp7020-02-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7020-02-lay-summary-nl.pdf?rev=8576729b1c0f41d79f14bcf4b9271dfb" target="_blank" rel="noopener">hp7020-02-lay-summary-dutch</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/hp7020-02-synopsis-red-final.pdf?rev=7727cfd24c404b69988f3b870ced8509" target="_blank" rel="noopener">hp7020-02 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="781a0be1-0369-48c9-a324-d344394bf7db" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP7030-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7030</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An exploratory relative bioavailability trial to assess the effect of food on the pharmacokinetics of 2 immediate release formulations of oxycodone (a new abuse-deterrent formulation and a marketed tablet) administered in healthy adult subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A comparison of how much oxycodone is in the blood of healthy adults after taking different tablets on a full stomach and on an empty stomach</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/3/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/24/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1203-4804</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2018-000771-33 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7030-01-lay-summary-english.pdf?rev=c375999b8a81467a99a56b32dbefe506&sc_lang=en" target="_blank" rel="noopener">hp7030-01-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7030-01-lay-summary-bulgarian.pdf?rev=ad78686c694e44e5a8a6e0d0d9c8b8e5&sc_lang=en" target="_blank" rel="noopener">hp7030-01-lay-summary-bulgarian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/hp7030-01-synopsis-red-final.pdf?rev=6e2b0d94d6f74a0fa9c173735accc173" target="_blank" rel="noopener">hp7030-01 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ac5bb7cb-e56f-4852-af03-a75c3ee9a129" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP7030-03</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7030</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A single-site, randomized, double-blind, double-dummy, active-comparator, placebo-controlled, 3-way crossover trial in adult non-dependent recreational opioid users to compare the intranasal abuse potential of immediate release abuse-deterrent and standard formulations of oxycodone</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A comparison of how likely it is that different tablets of oxycodone will be broken up and snorted by adults who sometimes take drugs for pleasure</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>7/24/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>11/20/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1203-4920</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03765346?term=NCT03765346&rank=1" class="" target="_blank" rel="noopener">NCT03765346</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7030-03-lay-summary-en.pdf?rev=80a2293aeeec4e5fb4cd75a54ef2d0ef&sc_lang=en" target="_blank" rel="noopener">hp7030-03 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7030-03-lay-summary-fr.pdf?rev=01c79a57a54e479eb1227c0597f3ba0a&sc_lang=en" target="_blank" rel="noopener">hp7030-03 lay summary french</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/hp7030-03-synopsis-red-final.pdf?rev=ab7060b645874e5b9d31f2668dfed5ce" target="_blank" rel="noopener">hp7030-03 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="039bc402-123d-41ea-8c7c-dd68c1d12b52" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8001-01; DCLF/TRMD-GRNN-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Adorlan®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT8001</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Study of Non-pharmacokinetic Interaction Between Diclofenac 25 mg and 25 mg Tramadol With the Fixed-dose Combination Tablets of the Two Drugs Administered to Healthy Subjects of Both Genders in Fasting State</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Pharmacokinetic Non-interaction Study With a Fixed-dose Combination Tablet With Tramadol and Diclofenac</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/7/2015</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>6/23/2015</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03766984?term=NCT03766984&rank=1" class="" target="_blank" rel="noopener">NCT03766984</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicosDetalle.asp?idsolicitud=1847" class="" target="_blank" rel="noopener">Mexico’s National Registry of Clinical Trials (RNEC)</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal Colombiana S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="efdcbd97-1881-4b7c-a086-be68f00a9846" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF8001-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Adorlan®, Adorlan Forte®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT8001</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, double-blind, multi-site, comparator-controlled, Phase III trial to evaluate the efficacy and safety of a fixed-dose combination of tramadol hydrochloride and diclofenac sodium in acute moderate to severe pain after third molar extraction</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Tramadol/diclofenac fixed-dose combination Phase III trial in acute pain after third molar extraction</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe acute pain after third molar extraction </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>8/26/2017</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/22/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1179-2333</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03714672?term=NCT03714672&rank=1" class="" target="_blank" rel="noopener">NCT03714672</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicosDetalle.asp?idsolicitud=3288" class="" target="_blank" rel="noopener">Mexico’s National Registry of Clinical Trials (RNEC)</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf8001-01-lay-summary-english.pdf?rev=db91fb86000943daa993b6ac5a6e9228" target="_blank" rel="noopener">kf8001-01-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf8001-01-lay-summary-spanish.pdf?rev=99ca91cd1aa947d3bed5fe0a48a07b3b" target="_blank" rel="noopener">kf8001-01-lay-summary-spanish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf8001-01-expert-summary.pdf?rev=407a220350d44f6191616cacae0f9c68" target="_blank" rel="noopener">kf8001-01-expert-summary</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="7bd191c0-adca-46ce-88f0-1e4343c668ff" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8002-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Tradol®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT8002</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Single Site Pharmacokinetic Non-interaction Study With Open-label, Randomized, Single-dose, Three-period, Six-sequence, Crossover Design to Compare Tramadol Hydrochloride 25 mg Capsules (Tradol [Trade Mark], Product of Gr&uuml;nenthal Mexico S.A. de C.V.) and Ketorolac Tromethamine 10 mg Tablets (Dolac [Trade Mark], Product of Siegfried Rhein, S.A. de C.V.) Administered Separately and Simultaneously in Healthy Volunteers Under Fasting Conditions<br /></td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Administration of Tramadol and Ketorolac Separately and Simultaneously to Assess a Potential Pharmacokinetic Interaction</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/5/2017</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>6/30/2017</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03767036?term=NCT03767036&rank=1" class="" target="_blank" rel="noopener">NCT03767036</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicosDetalle.asp?idsolicitud=3583" class="" target="_blank" rel="noopener">Mexico’s National Registry of Clinical Trials (RNEC)</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="241920a8-31ab-4934-84e8-e368b02bd3fc" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8013-01; PRG-02-GRU/PK-PVR-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT8013</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label, Randomized, Clinical Trial With Three Groups for the Characterization of Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td></td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td></td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03737656" class="" target="_blank" rel="noopener">NCT03737656</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="http://siipris03.cofepris.gob.mx/Resoluciones/Consultas/ConWebRegEnsayosClinicosDetalle.asp?idsolicitud=4745" class="" target="_blank" rel="noopener">Mexico’s National Registry of Clinical Trials (RNEC)</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="dba0bfd1-6d0a-44e6-9963-53b4da6a3bec" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8814-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Anulette & Anulette CD</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>levonorgestrel 0,15mg; ethinylestradiol 0,03mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossover bioequivalent trial of an oral formulation of Levonorgestrel and Ethinylestradiol coated tablets made by Laboratorios Andrómaco S.A., in the pharmaceutical form coated tablets of 0.15 / 0.03 mg, compared to the Microgynon CD formulation 0.15 / 0.03 mg dragees, considered for comparison reference, manufactured by Schering do Brasil, Química e Farmaceutica Ltda. For Bayer S.A. in 30 healthy volunteers after one dose of 2 tablets.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Contraception </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/24/2020</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>11/17/2020</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04230070 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="cae80c52-852d-4578-a9ae-778069d226c7" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8814-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Anulette 20</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Levonorgestrol 0,10mg; Ethynilestradiol 0,02mg</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A prospective, open and crossover bioequivalence trial of an oral formulation of Levonorgestrel and Ethinylestradiol coated tablets prepared by Laboratorios Andrómaco, in the pharmaceutical form of 0.10 / 0.02 mg coated tablets, with respect to to the Level® formulation, 100/20 mg coated tablets, considered as a comparison reference, manufactured by Biolab Sanus Farmacêutica Ltda., in 30 healthy volunteers after one dose of 2 tablets.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioavailability of Levonorgestrel/Ethinyl Estradiol Tablets 0.1 mg/0.02 mg With Regards to Reference Product</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Contraception </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/6/2020</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/22/2020</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> NCT04194905 </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Laboratorios Andromaco S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="631d31d6-0c5a-4459-b754-2d744bc51f60" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF10004/03</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Versatis®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Lidocaine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Safety and efficacy of lidocaine 5% medicated plaster in comparison with pregabalin in postherpetic neuralgia and diabetic polyneuropathic pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Postherpetic neuralgia and painful diabetic polyneuropathy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=19485723" class="" target="_blank" rel="noopener">19485723, 19480610, 19301937</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/4/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/14/2008</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00414349?term=NCT00414349&rank=1" class="" target="_blank" rel="noopener">NCT00414349</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003132-29" class="" target="_blank" rel="noopener">2006-003132-29</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ccea5805-1420-4398-8861-f9037d06dc07" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF7013-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Neridronic Acid</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, double-blind trial investigating the efficacy and safety of intravenous neridronic acid in subjects with complex regional pain syndrome type I (CRPS-I)</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Efficacy and safety of intravenous neridronic acid in CRPS-I</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Treatment of pain associated with CRPS-I </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/1/2015</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>11/2/2016</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1151-2181</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT02402530?term=NCT02402530&rank=1" class="" target="_blank" rel="noopener"> NCT02402530</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001915-37" class="" target="_blank" rel="noopener">2014-001915-37</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="http://" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-01-lay-summary-english.pdf?rev=6cdfc91310fe4fa5b1a57bb9873cc022" target="_blank" rel="noopener">kf7013-01 lay-summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-01-lay-summary-german.pdf?rev=71ea9a7e496b478bab993572608787c3" target="_blank" rel="noopener">kf7013-01 lay summary german</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="6706c771-cebe-4ec3-a2f2-df4d006851df" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF7013-03</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Neridronic Acid</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Safety of Intravenous Neridronic Acid in CRPS</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Complex Regional Pain Syndrome (CRPS) </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>12/20/2016</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/9/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1180-8099</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT02972359?term=NCT02972359&rank=1" class="" target="_blank" rel="noopener">NCT02972359</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=+2016-001164-11" class="" target="_blank" rel="noopener">2016-001164-11</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-03-lay-summary-english.pdf?rev=50a4f7dc15904e738f747f3496dc0ec6&sc_lang=en" target="_blank" rel="noopener">kf7013-03-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-03-lay-summary-german.pdf?rev=2cf20a5a241f44b1b15b4eac551b626f&sc_lang=en" target="_blank" rel="noopener">kf7013-03-lay-summary-german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf7013-03-expert-summary.pdf?rev=843a8a552efb492387825f9f9cfea2a4&sc_lang=en" target="_blank" rel="noopener">kf7013-03-expert-statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="d51dcf16-6c0c-4d3a-894d-7ae0670be2b9" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5503-88</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Relative bioavailability trial to investigate the pharmacokinetics of tapentadol following the administration of 3 prototype tapentadol&nbsp; 25 mg prolonged release (PR) granule formulations compared to a Palexia&reg; PR 25 mg tablet in healthy adult subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Comparison of blood concentrations of tapentadol from 4 prolonged release formulations (3 granule formulations and 1 tablet formulation) in healthy adult subjects</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/27/2015</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>6/15/2015</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1159-4436</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=+2012-005499-33+" class="" target="_blank" rel="noopener">2012-005499-33</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="9f049761-16e2-4557-8e84-e42218eabc8d" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5503-93</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, single-site, open-label, 2-way crossover, single-dose Phase I clinical trial to assess the bioequivalence of 2 tablets of a tapentadol 25 mg prolonged-release tablet formulation and 1 tablet of a tapentadol 50 mg prolonged-release tablet formulation in healthy male subjects under fed conditions</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A comparison of how much tapentadol is in the bloodstream of healthy men after taking different tablets on a full stomach</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/7/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/26/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1202-5348</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2017-003904-39 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp5503-93-lay-summary-english.pdf?rev=1589dba13240434cb584c5c9f38e6382&sc_lang=en" target="_blank" rel="noopener">hp5503-93-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp5503-93-lay-summary-dutch.pdf?rev=07bba980765f4a58848b3d2bf8cf36ea&sc_lang=en" target="_blank" rel="noopener">hp5503-93-lay-summary-dutch</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/hp5503-93-expert-statement.pdf?rev=5733e82c22c34751b6ef5efc4de3c171" target="_blank" rel="noopener">hp5503-93 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="90b2e80a-2728-481e-afd3-ac9d83d2888a" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/12</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized double-blind, placebo- and active-control, parallel-arm, Phase 3 study with controlled adjustment of dose to evaluate the efficacy and safety of tapentadol extended-release (ER) in subjects with moderate to severe chronic pain due to osteoarthritis of the knee</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic pain in subjects for whom an opioid treatment is clinically appropriate </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=28537501" class="" target="_blank" rel="noopener">28537501, 24985410, 24916058, 24353047, 23709304, 23340531</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/4/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/18/2008</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00486811?term=NCT00486811&rank=1" class="" target="_blank" rel="noopener">NCT00486811</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-005783-67" class="" target="_blank" rel="noopener">2006-005783-67</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ac4a4f0c-06e2-4ef6-bdd4-86b1fc6526cf" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/15</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral tapentadol PR in subjects with moderate to severe chronic malignant tumor-related pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe chronic malignant tumor-related pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25054392" class="" target="_blank" rel="noopener">25054392</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/13/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>6/4/2012</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00472303?term=NCT00472303&rank=1" class="" target="_blank" rel="noopener">NCT00472303</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004997-28" class="" target="_blank" rel="noopener">2006-004997-28</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="3b3a98db-c76e-4153-a830-617de5ad33e2" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/35</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, double-blind, parallel-arm, placebo- and comparator-controlled trial of the efficacy and safety of multiple doses of immediate-release (IR) CG5503 for post-operative pain following abdominal hysterectomy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Post-operative pain following abdominal hysterectomy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/19/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/11/2008</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00478023?term=NCT00478023&rank=1" class="" target="_blank" rel="noopener">NCT00478023</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-004998-95" class="" target="_blank" rel="noopener">2006-004998-95</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="7ad49e09-84ec-4c26-845d-c766db91e469" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/37</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, double-blind, parallel-group, multi-center, active- and placebo-controlled trial to evaluate the analgesic efficacy and safety of multiple doses of CG5503 IR for postoperative pain following bunionectomy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Post-operative pain following bunionectomy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/4/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/11/2007</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00609466?term=NCT00609466&rank=1" class="" target="_blank" rel="noopener">NCT00609466</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ba8c30a8-1796-4e4b-a159-c1f01a4d8c73" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/42</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with uncontrolled severe chronic pain due to osteoarthritis of the knee taking either WHO Step I or Step II analgesics or no regular analgesics</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic pain due to osteoarthritis of the knee </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22792000" class="" target="_blank" rel="noopener">22792000</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/21/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/2/2010</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00983073?term=NCT00983073&rank=1" class="" target="_blank" rel="noopener">NCT00983073</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010423-58" class="" target="_blank" rel="noopener">2009-010423-58</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="d4c867d9-da81-4812-b3c6-a327c16c6db3" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/44</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with uncontrolled severe chronic nociceptive, mixed or neuropathic low back pain taking either WHO Step I or Step II analgesics or no regular analgesics</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic nociceptive, mixed or neuropathic low back pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22443293" class="" target="_blank" rel="noopener">22443293</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/30/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/6/2010</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00983385?term=NCT00983385&rank=1" class="" target="_blank" rel="noopener">NCT00983385</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010427-12" class="" target="_blank" rel="noopener">2009-010427-12</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ddd72692-4c60-42a1-9589-eb89aa5d5a1e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/52</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label, single-arm, flexible dosing, Phase III trial, with oral tapentadol PR in subjects with chronic malignant tumor-related pain who have completed the Maintenance Period of the KF5503/15 trial</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Tapentadol in chronic malignant tumor related pain</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic malignant tumor-related pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>3/3/2011</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>5/8/2014</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01264887?term=NCT01264887&rank=1" class="" target="_blank" rel="noopener">NCT01264887</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-013291-46" class="" target="_blank" rel="noopener">2009-013291-46</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="37709768-c1af-4817-a46b-01386bf6717e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/53</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A multicenter, open-label trial to assess cognitive and psychomotor performance as surrogate parameters for driving ability under stable long-term treatment with tapentadol hydrochloride prolonged release tablets in subjects with chronic low back pain or osteoarthritis of the knee</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Psychomotor performance as a surrogate parameter for driving ability in subjects with chronic low back pain or osteoarthritis of the knee </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=25135385" class="" target="_blank" rel="noopener">25135385</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>2/26/2010</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/3/2010</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=+2009-015397-35+" class="" target="_blank" rel="noopener">2009-015397-35</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="93928d4c-48c3-45d5-8f38-a894c779744b" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/58</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain component</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Severe chronic low back pain with a neuropathic pain component </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=24738609" class="" target="_blank" rel="noopener">24738609, 24750558</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>3/23/2011</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/17/2012</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01352741?term=NCT01352741&rank=1" class="" target="_blank" rel="noopener">NCT01352741</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-019998-14" class="" target="_blank" rel="noopener">2010-019998-14</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="e29b3077-d642-4cf7-ad05-192718640f1e" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/60</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neuropathic pain component</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Severe chronic low back pain with a neuropathic pain component </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>3/22/2013</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/28/2014</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01838616?term=NCT01838616&rank=1" class="" target="_blank" rel="noopener">NCT01838616</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-002943-11" class="" target="_blank" rel="noopener">2012-002943-11</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="0bd063de-8398-4d3b-9442-bb489d8020de" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/62</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, double-blind, placebo-controlled parallel-group, multicenter trial to evaluate the efficacy and safety of multiple dose administration of an intravenous formulation of tapentadol in the treatment of acute pain following bunionectomy</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Treatment of acute pain following bunionectomy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/26/2011</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/14/2012</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01435577?term=NCT01435577&rank=1" class="" target="_blank" rel="noopener">NCT01435577</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="20b8633e-5c19-4def-b163-8734a50c0fcd" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/65</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A study to look at Tapentadol Oral Solution in Children and Adolescents in pain after Surgery</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Treatment of acute pain following bunionectomy </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>2/19/2015</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/14/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT02081391?term=NCT02081391&rank=1" class="" target="_blank" rel="noopener">NCT02081391</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004359-35" class="" target="_blank" rel="noopener">2012-004359-35</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf5503-65-expert-statement.pdf?rev=29acd3245b674a2fac2c121c6c4f6205" target="_blank" rel="noopener">kf5503-65 expert statement</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-bulgarian.pdf?rev=4954c7a5b7c84f789f52f71af5394e78" target="_blank" rel="noopener">kf5503-65 lay summary bulgarian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-croatian.pdf?rev=a2dbbf351c1a4aeeaf292abdb8b48678" target="_blank" rel="noopener">kf5503-65 lay summary croatian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-czech.pdf?rev=7bf1e2fa503b4c4caf87f601d4d01e16" target="_blank" rel="noopener">kf5503-65 lay summary czech</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-english.pdf?rev=67618652068e44b6ad71ed6e65691446" target="_blank" rel="noopener">kf5503-65 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-french.pdf?rev=48a3c5a3e719489687c25209fd2f2a2c" target="_blank" rel="noopener">kf5503-65 lay summary french</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-german.pdf?rev=f687f1056f554514b51491190dd9ce1e" target="_blank" rel="noopener">kf5503-65 lay summary german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-hungarian.pdf?rev=1bf944b8641c42a9b8920f15c3648e05" target="_blank" rel="noopener">kf5503-65, lay summary hungarian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-polish.pdf?rev=8be63ae491524dcf878023664ede7d2e" target="_blank" rel="noopener">kf5503-65 lay summary polish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-65-lay-summary-spanish.pdf?rev=96da24c20de34e8382fc7edc1713a5ee" target="_blank" rel="noopener">kf5503-65 lay summary spanish</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="024f72f1-6d82-460e-802f-900ee506be87" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503-66</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An open-label trial, enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment, to evaluate the safety and efficacy of tapentadol PR versus morphine PR, followed by an open-label extension</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A study to look at Tapentadol Tablets in Children and Adolescents in pain</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/29/2015</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/15/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1154-4572</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT02151682?term=NCT02151682&rank=1" class="" target="_blank" rel="noopener">NCT02151682</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2012-004360-22" class="" target="_blank" rel="noopener">2012-004360-22</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf5503-66-expert-summary.pdf?rev=4a21a6064171463d8cf1ac7c7e2f0b49" target="_blank" rel="noopener">kf5503-66-expert-summary</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-bulgarian.pdf?rev=7ea4af43d5ad4dd8be546212da9e4255&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-bulgarian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-english.pdf?rev=b9573dcadad8427c9aebd0047fb5ce70&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-french-be.pdf?rev=07a9502f80684ef4bc1670273113dee1&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-french-BE</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-french-fr.pdf?rev=160274d829a646e2a8a98054ef2f4296&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-french-FR</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-german.pdf?rev=a23c9c1fcd7849bf954f8cc7dd6a6277&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-hungarian.pdf?rev=2d371aaf952f4a5fb6c9f65fefa792c8&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-hungarian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-italian.pdf?rev=57719e3335494c79a447bc49d23f18a1&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-italian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-portuguese.pdf?rev=0dde89b625304a05820b079a532f84c0&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-portuguese</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-spanish-cl.pdf?rev=a162879f0ab34ebf99ebdb89f9238e00&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-spanish-CL</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-66-lay-summary-spanish-es.pdf?rev=6f0e20ac65bd43f4960dabf023674984&sc_lang=en" target="_blank" rel="noopener">kf5503-66-lay-summary-spanish-ES</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="963b3222-413d-4f09-bd12-cfec58610f25" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/68</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label evaluation of the pharmacokinetic profile, safety, and efficacy of tapentadol oral solution for the treatment of post-surgical pain in children and adolescents aged from 2 years to less than 18 years</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Post-surgical pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/15/2012</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/24/2014</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01729728?term=NCT01729728&rank=1" class="" target="_blank" rel="noopener">NCT01729728</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-002016-27" class="" target="_blank" rel="noopener">2013-002016-27</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="a2c58661-53a2-4d01-95ee-cd2ddf337a4c" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503-73</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of intravenous tapentadol solution for injection for the treatment of post-surgical pain in children aged from birth to less than 2 years, including preterm neonates</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Use of intravenous tapentadol solution for injection for pain after surgery in children from newborn to less than 2 years old, including preterm babies</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe acute post-operative pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>4/23/2015</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/27/2018</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1157-3228</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-002259-24" class="" target="_blank" rel="noopener">2014-002259-24</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf5503-73-expert-summary.pdf?rev=7b482f7120cc430082e5f3f97732083f" target="_blank" rel="noopener">kf5503-73-expert-summary</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-73-lay-summary-english.pdf?rev=980c7c03f3bb42b6876fcbc3c0cbd032&sc_lang=en" target="_blank" rel="noopener">kf5503-73-lay-summary-english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-73-lay-summary-french.pdf?rev=fab4ac367591408a88b2412b6193bde5&sc_lang=en" target="_blank" rel="noopener">kf5503-73-lay-summary-french</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-73-lay-summary-hungarian.pdf?rev=924b3d88b180414482341902bf611d2a&sc_lang=en" target="_blank" rel="noopener">kf5503-73-lay-summary-hungarian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-73-lay-summary-polish.pdf?rev=653e8609cbe64dc180ea63b6f5512821&sc_lang=en" target="_blank" rel="noopener">kf5503-73-lay-summary-polish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-73-lay-summary-spanish.pdf?rev=8e56839a90634edca8daff77c49e45ab&sc_lang=en" target="_blank" rel="noopener">kf5503-73-lay-summary-spanish</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="c67cca70-f2f8-45c6-97cd-a7a790bfdd1b" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503-75</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label investigation of the pharmacokinetic profile, safety, tolerability, and efficacy of multiple administrations of tapentadol oral solution used for treatment of acute pain in children aged 2 years to less than 7 years</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A clinical trial to find out how much tapentadol is in the blood of children who take tapentadol every 4 hours to treat short-term pain</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe acute pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>9/9/2019</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/6/2020</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1225-7869</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000205-77/PL" class="" target="_blank" rel="noopener">2019-000205-77</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-75-lay-summary-en.pdf?rev=7aed364b5a574f0bb83667e91a2e111a" target="_blank" rel="noopener">kf5503-75 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-75-lay-summary-pl.pdf?rev=bdc7c9611d0a4d78abab6c565de34f78" target="_blank" rel="noopener">kf5503-75 lay summary polish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf5503-75-ictr-synopsis-red.pdf?rev=136e4456d961440c947e71d45f67a6f2" target="_blank" rel="noopener">kf5503-75 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="e2176700-a5b1-4f15-bfc8-60880b80ce30" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>FO-PK 401</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Tramal®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tramadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Serum concentrations of tramadol and its metabolite Ml in children after intravenous or caudal extradural administration of tramadol-HCL</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Children undergoing elective limb surgery or urogenital surgery </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>3/1/1995</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>10/31/1995</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> Paediatric studies in scope of Art45 document reference 45000 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=&art45=1" class="" target="_blank" rel="noopener">EU Article 45 Pediatric database</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="80887cad-2470-4581-a0cf-75f043ca621c" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>TRA-RSA-2</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Tramal®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tramadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>The assessment of the safety and efficacy of tramadol suppositories compared to paracetamol suppositories when administered as premedication together with midazolam in subjects aged 3 to 7 years</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Children undergoing multiple dental extractions under general anaesthesia </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>7/30/2001</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/28/2003</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> Paediatric studies in scope of Art45 document reference 44997 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=&art45=1" class="" target="_blank" rel="noopener">EU Article 45 Pediatric database</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="6a5180d6-4422-44ae-a2ac-4bf58f7e69df" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>WIS-AL-TRA86-04-95</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Tramal®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tramadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open clinical study on the analgesic efficacy and safety of tramadol (TRAMAL) in children with post-operative pain after abdominal surgery</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Open clinical study on the analgesic efficacy of tramadol (TRAMAL) in children with post-operative pain after abdominal surgery</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Post-operative pain after abdominal surgery </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Completed</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/23/1995</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>3/29/1996</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> Paediatric studies in scope of Art45 document reference 45006 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=&art45=1" class="" target="_blank" rel="noopener">EU Article 45 Pediatric database.</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>4</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="4a666dcf-5b31-46bc-9718-76a9d47d7621" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF10004/08</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Versatis®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>5% Lidocaine medicated plaster</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Lidocaine 5% medicated plaster for the topical treatment of localized chronic postoperative neuropathic pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Localized chronic postoperative neuropathic pain (PoNP) </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>8/24/2010</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>11/27/2012</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01155986?term=NCT01155986&rank=1" class="" target="_blank" rel="noopener">NCT01155986</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-016337-10" class="" target="_blank" rel="noopener">2009-016337-10</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="e1ee3f3a-aa0c-49e8-ad4b-5c8c6526c0fe" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5303/10</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Multiple dose bioequivalence trial comparing a new analgesic transdermal patch formulation to an analgesic patch</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Multiple Dose Trial Comparing the Plasma Levels of Two Different Analgesic Transdermal Patch Formulations</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/10/2006</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/20/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00387777?term=NCT00387777&rank=1" class="" target="_blank" rel="noopener">NCT00387777</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2006-003177-27 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="34cfa822-69d4-4d9a-b97c-2da8c00c8253" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5303/11</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Single dose bioequivalence trial comparing a new analgesic transdermal patch formulation to an analgesic reference patch</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/6/2006</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>12/14/2006</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00388219?term=NCT00388219&rank=1" class="" target="_blank" rel="noopener">NCT00388219</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2006-003178-90 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="80307490-ae3f-481f-825a-11279d33f180" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5303/12</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Multiple dose bioequivalence trial comparing a down-scaled new analgesic transdermal patch formulation to an analgesic reference patch</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/21/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/4/2007</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00469053?term=NCT00469053&rank=1" class="" target="_blank" rel="noopener">NCT00469053</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2007-000667-22 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="a15ceacb-7335-4b50-a00e-1d910d981a0d" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP5303/13</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Burprenorphine</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Single dose bioequivalence trial comparing a down-scaled new analgesic transdermal patch formulation to an analgesic reference patch</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/29/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/10/2007</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00469404?term=NCT00469404&rank=1" class="" target="_blank" rel="noopener">NCT00469404</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2007-000668-26 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="1b6283ac-89b7-4889-b1ea-281c692aa92d" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF6010/01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT6010</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Peripheral neuropathic pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>2/23/2012</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/18/2013</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT01485094?term=NCT01485094&rank=1" class="" target="_blank" rel="noopener"> NCT01485094</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-002092-42" class="" target="_blank" rel="noopener"> 2011-002092-42</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="11132a66-823d-477c-9697-407288731099" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP6015-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT6015</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A randomized, single-center, double-blind, placebo- and active-controlled (Part 1) and open-label (Part 2) Phase I trial to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT6015 in healthy male subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single doses of GRT6015 in healthy men</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>7/19/2017</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/1/2017</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1192-1860</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2017-000541-40 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp6015-01-lay-summary-english.pdf?rev=79f3958c7c5444efb331f0bbb409d3a6" target="_blank" rel="noopener">hp6015-01 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp6015-01-lay-summary-german.pdf?rev=f7c6e730fa564ff8bab40e1d58591ff2" target="_blank" rel="noopener">hp6015-01 lay summary german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/hp6015-01-expert-statement.pdf?rev=b275759eb662474793a860a6d1be3df5" target="_blank" rel="noopener">hp6015-01 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="b54669e8-e1a5-461c-9fe2-38bbb09a6f2a" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF7021-04</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>GRT7021</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7021</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A Randomized, Open-label, Multi-center, Controlled Clinical Study to Compare MAR-CUTIS with Dermabond Advanced in Closure of Surgical Incisions and Lacerations up to 15cm</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Clinical Study to Compare MAR-CUTIS With Dermabond Advanced</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Closure of Surgical Incisions and Lacerations </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/30/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>9/4/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03688880?term=NCT03688880&rank=1" class="" target="_blank" rel="noopener">NCT03688880</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="http://adhesys-medical.com/" class="" target="_blank" rel="noopener">CUTIS topical skin adhesive – learn more about CUTIS</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>Pivotal</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf7021-04-expert-statement.pdf?rev=b27eba216298421b9e71a1bfcd085558" target="_blank" rel="noopener">kf7021-04 expert statement </a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7021-04-lay-summary-english.pdf?rev=eb981875f9f842d697ceef91d3388e1b" target="_blank" rel="noopener">kf7021-04 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7021-04-lay-summary-english-for-uk.pdf?rev=5c7a7517a1de46d28a8dfa84beefb5d1" target="_blank" rel="noopener">kf7021-04 lay summary english for UK</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7021-04-lay-summary-french.pdf?rev=a057292b301f4c2f97d0aa1bba787bd5" target="_blank" rel="noopener">kf7021-04 lay summary french</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7021-04-lay-summary-german.pdf?rev=87eb7771658f4aedbcf4faaf46f71dfe" target="_blank" rel="noopener">kf7021-04 lay summary german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7021-04-lay-summary-spanish.pdf?rev=d241f3ace4534477bc0283a6a191f6ef" target="_blank" rel="noopener">kf7021-04 lay summary spanish</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="e6af65e4-6e9c-4cb5-ad4b-ccad4cc51d73" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP7030-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7030</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An exploratory relative bioavailability trial of different amounts of 2 immediate release formulations of oxycodone (a new abuse-deterrent formulation and a marketed tablet) administered under fasted conditions in healthy adult subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A comparison of how much oxycodone is in the blood of healthy adults after taking different amounts of different tablets on an empty stomach</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>1/7/2019</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/26/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1203-4898</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> 2018-000772-16 </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7030-02-lay-summary-english.pdf?rev=675f9a86ecc54d68b1bcce6709da0fe3" target="_blank" rel="noopener">hp7030-02 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/hp7030-02-lay-summary-bulgarian.pdf?rev=2b212093a64940b0a0fc47d216d593eb" target="_blank" rel="noopener">hp7030-02 lay summary bulgarian </a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/hp7030-02-synopsis-red-final.pdf?rev=3e309fb9136a44eb867ed7452d44f301" target="_blank" rel="noopener">hp7030-02 expert statement</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="2c18b982-3ebb-4ea0-82d8-d9ef21fe8dd5" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF7013-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Neridronic Acid</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Efficacy and safety of intravenous neridronic acid in CRPS</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Complex Regional Pain Syndrome (CRPS) </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/30/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>7/31/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1187-8036</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/record/NCT03530345?term=kf7013-02&rank=1" class="" target="_blank" rel="noopener">NCT03530345</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=kf7013-02" class="" target="_blank" rel="noopener">2016-003833-91</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=7665&isClinicalTrial=True" class="" target="_blank" rel="noopener">Australien New Zealand Clinical Trials Registry (ANZCTR)</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/additional-trial-information/media-statement-discontunuation-of-neridronate-trials.pdf?rev=93c4eb11e85f4d8ba6d2dd9111e31584" target="_blank" rel="noopener">Media Statement_Discontinuation of Neridronate trials</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf7013-02-expert-statement.pdf?rev=d75a78caf1bb4df4b1828d2664e7a726" target="_blank" rel="noopener">kf7013-02 expert statement</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-english.pdf?rev=f51a6587c2c74bb4b43eee529d88ce8e" target="_blank" rel="noopener">kf7013-02 lay summary english</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-english-for-australia.pdf?rev=613009c28b824efcb550e1e633cf01f3" target="_blank" rel="noopener">kf7013-02 lay summary english for Australia</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-english-for-new-zealand.pdf?rev=a960cef0b2f4491ab1303ceca0457875" target="_blank" rel="noopener">kf7013-02 lay summary english for New Zealand</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-french.pdf?rev=95b4bfb6562b4524b1b94a9a9970b9ab" target="_blank" rel="noopener">kf7013-02 lay summary french</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-german.pdf?rev=455fd155654848df89e84f2642b4791e" target="_blank" rel="noopener">kf7013-02 lay summary german</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-korean.pdf?rev=506c1a4f6a4e49049d84e3ab18e9ca98" target="_blank" rel="noopener">kf7013-02 lay summary korean</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-02-lay-summary-spanish.pdf?rev=a1adc15f2f624bad81cdd21844a0c420" target="_blank" rel="noopener">kf7013-02 lay summary spanish</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="45001c9b-ce38-4793-89c4-30043266d7c1" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF7013-04</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Neridronic Acid</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Placebo-controlled efficacy and safety trial of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Efficacy and safety of intravenous neridronic acid in CRPS</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Complex Regional Pain Syndrome (CRPS) </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>5/31/2018</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/1/2019</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1203-5020</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03560986?term=NCT03560986&rank=1" class="" target="_blank" rel="noopener">NCT03560986</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=kf7013-04" class="" target="_blank" rel="noopener">2017-004244-37</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/additional-trial-information/media-statement-discontunuation-of-neridronate-trials.pdf?rev=93c4eb11e85f4d8ba6d2dd9111e31584" target="_blank" rel="noopener">Media Statement_Discontinuation of Neridronate trials</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/expert-summaries/kf7013-04-expert-statement.pdf?rev=9a167ef2b1b94ed2887cd3d95c794f52" target="_blank" rel="noopener">kf7013-04 expert statement</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-czech.pdf?rev=6ff2cf136d014b44acfaff9d1a70858e" target="_blank" rel="noopener">kf7013-04 lay summary czech</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-english.pdf?rev=d1991b0f3f104bf4bd291a8f47543b0f" target="_blank" rel="noopener">kf7013-04 lay summary english </a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-english-for-uk.pdf?rev=38752585f2a4421290d259565d44d063" target="_blank" rel="noopener">kf7013-04 lay summary english for UK</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-french-for-canada.pdf?rev=8ecf52968109495087f646ba7cac1bd9" target="_blank" rel="noopener">kf7013-04 lay summary french for Canada</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-polish.pdf?rev=36c87a29179849da87f69f422ce95563" target="_blank" rel="noopener">kf7013-04 lay summary polish</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-serbian.pdf?rev=84bac507f3e34d9f9a77f9635e96e95e" target="_blank" rel="noopener">kf7013-04 lay summary serbian</a> </div> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf7013-04-lay-summary-slovakian.pdf?rev=b93741d4b0c241849521fd000c6b0de4" target="_blank" rel="noopener">kf7013-04 lay summary slovakian</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="1b9be24b-c74e-4ea0-84de-17b07c6cf2a7" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/16</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td><p>A randomized withdrawal, active- and placebo-controlled, doubleblind, multi-center Phase III trial assessing safety and efficacy of oral tapentadol PR(a) in subjects with moderate to severe chronic malignant tumor-related pain</p> <p>(a) PR means Prolonged Release and is the recommended nomenclature for use in Europe. ER means Extended Release and is the recommended nomenclature for use in the United States. &ldquo;PR&rdquo; is synonymous with &ldquo;ER&rdquo; and is interchangeable in the report</p></td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe chronic malignant tumor-related pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>6/29/2007</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>2/2/2009</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00505414?term=NCT00505414&rank=1" class="" target="_blank" rel="noopener">NCT00505414</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-001985-34" class="" target="_blank" rel="noopener">2007-001985-34</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="31af82a6-6217-46d5-ae70-d922df060e2a" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/43</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic pain due to osteoarthritis of the knee taking WHO Step III analgesics but showing a lack of tolerability</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic pain due to osteoarthritis of the knee </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23912473" class="" target="_blank" rel="noopener">23912473</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/2/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>8/12/2010</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00982280?term=NCT00982280&rank=1" class="" target="_blank" rel="noopener">NCT00982280</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010425-39" class="" target="_blank" rel="noopener">2009-010425-39</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="ff1a1913-fe8c-47fa-9e9b-6a73ef685bb5" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503/45</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>An evaluation of the effectiveness and tolerability of tapentadol hydrochloride prolonged release, and tapentadol hydrochloride immediate release on demand, in subjects with severe chronic nociceptive, mixed or neuropathic low back pain taking WHO Step III analgesics but showing a lack of tolerability</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>--</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Chronic nociceptive, mixed or neuropathic low back pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=23475406" class="" target="_blank" rel="noopener">23475406</a> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>10/30/2009</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>1/21/2011</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT00986258?term=NCT00986258&rank=1" class="" target="_blank" rel="noopener">NCT00986258</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2009-010428-25" class="" target="_blank" rel="noopener">2009-010428-25</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>3</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="429684fd-4dbe-4e8a-9f95-4a3cfa566c21" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>KF5503-72</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>Palexia®, Nucynta®, Yantil®</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>Tapentadol</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Open-label evaluation of the population pharmacokinetic profile, safety, tolerability, and efficacy of tapentadol oral solution for the treatment of post-surgical pain in children aged from birth to less than 2 years.</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Use of tapentadol oral solution for pain after surgery in children from newborn to less than 2 years old</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> Moderate to severe acute post-operative pain </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Terminated</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>Yes</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td>11/5/2014</td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td>11/3/2016</td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1153-1662</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT02221674?term=NCT02221674&rank=1" class="" target="_blank" rel="noopener">NCT02221674</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> <a href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-000623-24" class="" target="_blank" rel="noopener">2014-000623-24</a> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>2</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> <div> <a href="/-/media/projects/corporatewebsite/com/pdf/clinicaltrialportal/lay-summaries/kf5503-72-lay-summary-english-polish.pdf?rev=6f94a0874e454e98b88a3f8e4ab7ef9e" target="_blank" rel="noopener">KF5503-72 lay summary-english-polish</a> </div> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="1ac700d9-98ac-44f7-8e6a-1ed06d2e20af" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP7014-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7014</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A relative bioavailability trial to investigate the pharmacokinetics of two immediate release fixed dose combinations of hydrocodone bitartrate and acetaminophen (a new abuse deterrent tablet and a marketed tablet) administered under fasted and fed conditions in healthy male and female adult subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A comparison of plasma concentrations of hydrocodone and acetaminophen after administration of a new and a marketed tablet formulation under fasted and fed conditions in healthy adults</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Withdrawn</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td></td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td></td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1183-5343</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03137017?term=NCT03137017&rank=1" class="" target="_blank" rel="noopener">NCT03137017</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener">--</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="262191cf-11e9-4a29-a4dc-2f70c6024d2f" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP7014-02</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT7014</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>A Relative Bioavailability Trial to Investigate the Pharmacokinetics of Different Amounts of Tablets of Two Immediate Release Fixed Dose Combinations of Hydrocodone Bitartrate 5 mg/Acetaminophen 325 mg (a New Abuse Deterrent Tablet and a Marketed Tablet) Under Fasted Conditions in Healthy Male and Female Adult Subjects</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Withdrawn</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> -- </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td></td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td></td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>U1111-1184-8922</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03137030?term=NCT03137030&rank=1" class="" target="_blank" rel="noopener">NCT03137030</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener">--</a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal GmbH</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="3c5276f9-173f-4119-9f28-e0e9d9a44021" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8010-01; ESTNMG-04-GRU</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT8010</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Single Site, Open-label, Randomized, Two Treatments, Two Periods, Two Sequences, Crossover Single-dose Trial to Investigate the Bioequivalence of Two Oral Formulations of a Fixed-dose Combination Tablet Containing 1.5 mg Estradiol and 2.5 mg Nomegestrol Acetate (Product of Laboratorios Andromaco S.A. [Test Product] Versus Stezza, Product of Merck Sharp and Dohme Farmaceutica Ltda. [Reference Product]) in Postmenopausal Women Under Fasting Conditions</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>Bioequivalence of Two Fixed-dose Combination Tablets Containing Estradiol and Nomegestrol Acetate</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Withdrawn</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td></td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td></td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td>--</td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03749733?term=NCT03749733&rank=1" class="" target="_blank" rel="noopener">NCT03749733</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> <div class="small-12 columns"> <div class="columns small-2"></div> <div class="columns small-8"> <table data-clinical-trial-table-id="18c29425-dce0-4b89-b264-f94c0f904f5c" class="detailsTable" style="display: none;" aria-describedby="mydesc"> <thead> <tr> <th>Key Column Headline</th> <th>Value Column Headline</th> </tr> </thead> <tbody> <tr> <td style="min-width: 200px;"><strong>Trial Identifier (Sponsor):</strong></td> <td><strong>HP8012-01</strong></td> </tr> <tr> <td><strong>Trade Name</strong></td> <td>--</td> </tr> <tr> <td><strong>INN / Sponsor substance code:</strong></td> <td>GRT8012</td> </tr> <tr> <td><strong>Trial title:</strong></td> <td>Single Site, Open-label, Randomized, Two Treatments, Two Periods, Two Sequences, Crossover Trial to Evaluate the Bioequivalence of Two Delayedrelease Oral Formulations of a Fixed Combination of Doxylamine Succinate 10 mg/Pyridoxine Hydrochloride 10 mg (Test Product: Product of Tecnandina, S.A. TENSA; Reference Product: Diclegis (Registered Trademark) Product of Duchesnay Inc.) After a Single Administration of Two Tablets to Healthy Women Under Fasting Conditions</td> </tr> <tr> <td><strong>Brief title:</strong></td> <td>A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions</td> </tr> <tr> <td><strong>Trial indication:</strong></td> <td> -- </td> </tr> <tr> <td><strong>Trial status:</strong></td> <td>Withdrawn</td> </tr> <tr> <td><strong>Results posted:</strong></td> <td>No</td> </tr> <tr> <td><strong>PubMed unique identifier [PMID]:</strong></td> <td> </td> </tr> <tr> <td><strong>First subject enrolled:</strong></td> <td></td> </tr> <tr> <td><strong>Last subject completed: </strong></td> <td></td> </tr> <tr> <td><strong>UTN (WHO):</strong></td> <td></td> </tr> <tr> <td><strong>ClinicalTrials.gov Identifier:</strong></td> <td> <a href="https://clinicaltrials.gov/ct2/show/NCT03905564?term=NCT03905564&rank=1" class="" target="_blank" rel="noopener">NCT03905564</a> </td> </tr> <tr> <td><strong>Eudra CT Identifier:</strong></td> <td> </td> </tr> <tr> <td><strong>Other:</strong></td> <td> <a href="" class="" target="_blank" rel="noopener"></a> </td> </tr> <tr> <td><strong>Available for data sharing:</strong></td> <td>No</td> </tr> <tr> <td><strong>Trial phase:</strong></td> <td>1</td> </tr> <tr> <td><strong>Trial sponsor:</strong></td> <td>Grünenthal, S.A.</td> </tr> <tr> <td><strong>Trial documents:</strong></td> <td data-list="TrialDocuments"> </td> </tr> </tbody> </table> </div> <div class="columns small-2"></div> </div> </div> </div> </div> <div class="small-12 medium-12 columns"> </div> </div> </div> </div> </div> </div> </div> </div> <footer class="footer-site" id="page-footer"> <div class="row"> <div class="large-3 medium-12 columns"> <div class="footer-site__copy"> <p class="footer-site__copy__highlight"> This website is for all those with an interest in the global business of Grünenthal </p> </div> <a href="/" class="footer-site__logo"> <img class="footer-site__logo" src="/-/media/projects/shared/logos/grt/grunenthal-altes-logo-footer.svg?rev=ba8e8107aa93419bae6b36df21521a7f" width="" height="" alt="Grünenthal Group" /> </a> <a href="http://opioid-info.com" target="_blank" class="footer-site__c4c"> <img class="footer-site__logo-c4c" src="/-/media/projects/shared/logos/other/opioid-disclaimer-usage-logo-url-white.png?rev=238ca1af6fe24e20b735500c01628aa0" width="169" height="67" alt="opioid-info.com logo" /> </a> </div> <div class="large-3 columns"> <h2 class="footer-site__sub-title">Sites & Channels</h2> <ul class="footer-site__links"> <li><a href="https://careers.grunenthal.com" target="_blank" class="link-external ">Careers</a></li> <li><a href="https://www.linkedin.com/company/gruenenthal" target="_blank" class="link-external ">LinkedIn</a></li> <li><a href="https://www.instagram.com/grunenthal" target="_blank" class="link-external ">Instagram</a></li> </ul>  </div> <div class="large-3 columns"> <h2 class="footer-site__sub-title">Services</h2> <ul class="footer-site__links"> <li><a href="/en/footer-links/contact" class=" ">Contact form</a></li> <li><a href="/en/footer-links/drug-safety-reporting" class=" ">Reporting side effects</a></li> <li><a href="/en/footer-links/medical-information-enquiry" class=" ">Medical information request</a></li> <li><a href="https://careers.grunenthal.com/go/All-jobs/4703901" target="_blank" class="link-external ">Job offers</a></li> </ul>  </div> <div class="large-3 columns"> <h2 class="footer-site__sub-title">Memberships</h2> <ul class="footer-site__links"> <li><a title="https://efpia.eu/" href="https://efpia.eu/" target="_blank" class="link-external ">EFPIA</a></li> <li><a href="https://www.ifpma.org" target="_blank" class="link-external ">IFPMA</a></li> <li><a href="https://pscinitiative.org/home" target="_blank" class="link-external ">PSCI</a></li> </ul> <nav class="footer-site__social-links footer-site__social-links--mobile"> <a href="https://www.youtube.com/channel/UCyLvh5Nldpbsojxa8URjqVg" class="" target="_blank"> <span class="icon-Youtube"></span> <span class="text">Youtube</span> </a> <a href="https://www.facebook.com/Caring-for-Change-1975323459367353/" class="" target="_blank"> <span class="icon-Facebook"></span> <span class="text">Facebook</span> </a> </nav> </div> </div> <div class="row"> <div class="large-2 columns"> <div class="p--x-small footer-site__copyright align-left"> </div> </div> <div class="large-8 columns"> <div class="p--x-small footer-site__copyright"> Grünenthal 2025 © <nav class="footer__navigation-inline"> <a href="/en/footer-links/general-terms-and-conditions" class=" ">General Terms and Conditions</a> <a href="/en/footer-links/disclaimer" class=" ">Terms of Use</a> <a href="/en/footer-links/privacy-statement" class=" ">Website Privacy Statement</a> <a href="/en/footer-links/other-privacy-statements" class=" ">Other Privacy Statements</a> <a href="/en/footer-links/imprint" class=" ">Imprint</a> <a href="/en/footer-links/sitemap" class=" ">Sitemap</a> </nav> </div> </div> <div class="large-2 columns"> <div class="p--x-small footer-site__copyright align-right"> </div> </div> </div> </footer> </div> <script src="/-/media/base-themes/core-libraries/scripts/optimized-min.js?rev=7b3ac22a91bf40ee96ba909960edcdc3&t=20240826T134323Z&hash=832F6CAE252D32012BC53172775953C5"></script><script src="/-/media/base-themes/xa-api/scripts/optimized-min.js?rev=f7bf558146a5478c8ccc889f8f11e30d&t=20240826T134038Z&hash=1175B9A8CD6DE119F13D009A7C007794"></script><script src="/-/media/base-themes/main-theme/scripts/optimized-min.js?rev=f357be036f9e4e7eb292764729fa8062&t=20250222T204332Z&hash=537F8474AB346A0ECD74C98DF04BDF37"></script><script src="/-/media/base-themes/maps/scripts/optimized-min.js?rev=4c5d766b3c9a4be9b324607abef9b2ae&t=20250222T210047Z&hash=203FA28E9EDB379BA5EB9716C40BB9CA"></script><script src="/-/media/base-themes/searchtheme/scripts/optimized-min.js?rev=9c1c488e000746e98fb01d0ab70b38db&t=20240826T134126Z&hash=609C1777E96F662945F876374AEC219B"></script><script src="/-/media/themes/grunenthal/groupsite/toolkit/scripts/optimized-min.js?rev=72dc4ba847c04ccaaac8629911b85ae5&t=20241212T112156Z&hash=FB51C529AAD545886A5B672B5E239ED3"></script>  <style> .Gx-popup-component { position: fixed; height: 100%; width: 100%; z-index: 9999; top: 0rem; left: 0rem; display: none; } .Gx-popup-component .button { border: solid 0.125rem transparent; border-radius: 0rem; cursor: pointer; display: inline-block; font-size: 1.0625rem; line-height: 1.3125rem; padding: 0.3125rem 0.625rem 0.3125rem 0.3125rem; text-decoration: none; font-weight: 500; } .Gx-popup-component .button > [class*=' icon-'], .Gx-popup-component .button > [class^=icon-] { border-radius: 0rem; display: inline-block; font-size: 0.8125rem; font-weight: 700; height: 1.5rem; line-height: 1.5rem; text-align: center; vertical-align: initial; width: 1.5rem; } .Gx-popup-component .button.is-focus, .Gx-popup-component .button:focus { outline: 0.0625rem solid; outline-color: #00874b; outline-style: outset; } .Gx-popup-component .button-p1 { border-radius: 3rem; color: #282828; } .Gx-popup-component .button-p1 > [class*=' icon-'], .Gx-popup-component .button-p1 > [class^=icon-] { background-color: #00a059; border-radius: 3rem; color: #fefefe; } .Gx-popup-component .button-p1 .button__elipsis { color: #00a059; display: inline-block; position: relative; top: -0.1875rem; } .Gx-popup-component .button-p1.is-focus, .Gx-popup-component .button-p1:focus { background-color: #00a059; border-color: #00a059; -webkit-box-shadow: 0rem 0rem 0rem 0.125rem #006d3d; box-shadow: 0rem 0rem 0rem 0.125rem #006d3d; color: #f4f4f4; outline: 0rem none; } .Gx-popup-component .button-p1.is-focus > [class*=' icon-'], .Gx-popup-component .button-p1.is-focus > [class^=icon-] { background-color: #f4f4f4; color: #282828; } .Gx-popup-component .button-p1:focus > [class*=' icon-'], .Gx-popup-component .button-p1:focus > [class^=icon-] { background-color: #f4f4f4; color: #282828; } .Gx-popup-component .button-p1.is-focus::after, .Gx-popup-component .button-p1:focus::after { display: none; } .Gx-popup-background { position: fixed; height: 100%; width: 100%; background: rgba(40, 40, 40, 0.6); } .Gx-popup { position: fixed; top: 50%; left: 50%; -webkit-transform: translate(-50%, -50%); -ms-transform: translate(-50%, -50%); transform: translate(-50%, -50%); width: 50%; background: white; -webkit-box-shadow: 0rem 0.625rem 1rem 0rem rgba(0, 0, 0, 0.2), 0rem 0.375rem 1.25rem 0rem rgba(0, 0, 0, 0.19); box-shadow: 0rem 0.625rem 1rem 0rem rgba(0, 0, 0, 0.2), 0rem 0.375rem 1.25rem 0rem rgba(0, 0, 0, 0.19); border-radius: 0.625rem; padding: 1.25rem; } .Gx-popup-button { width: 45%; position: relative; } .Gx-popup-button.left { float: left; text-align: left; } .Gx-popup-button.right { float: right; text-align: right; } .Gx-popup-data { text-align: center; color: #00a059 !important; } .Gx-popup-button-cancel.button-p1 .button__elipsis, .Gx-popup-button-cancel.button-p1 { color: #d50808 !important; } .Gx-popup-button-cancel.button-p1 > [class*=' icon-'], .Gx-popup-button-cancel.button-p1 > [class^=icon-], .Gx-popup-button-cancel.button-p1:hover, .Gx-popup-button-cancel.button-p1:hover .button__elipsis { background-color: #d50808 !important; color: white !important; text-decoration: none; } .Gx-popup-button-cancel.button-p1:hover > [class*=' icon-'], .Gx-popup-button-cancel.button-p1:hover > [class^=icon-] { background-color: white !important; color: #d50808 !important; } .button-p1.Gx-popup-button-ok { float: right; } .Gx-popup-button-ok.button-p1 .button__elipsis, .Gx-popup-button-ok.button-p1 { color: #00a059 !important; } .Gx-popup-button-ok.button-p1 > [class*=' icon-'], .Gx-popup-button-ok.button-p1 > [class^=icon-], .Gx-popup-button-ok.button-p1:hover, .Gx-popup-button-ok.button-p1:hover .button__elipsis { background-color: #00a059 !important; color: white !important; } .Gx-popup-button-ok.button-p1:hover > [class*=' icon-'], .Gx-popup-button-ok.button-p1:hover > [class^=icon-] { background-color: white !important; color: #00a059 !important; } </style> <div class="Gx-popup-component Gx-popup-component--external-link"> <div class="Gx-popup-background"> </div> <div class="Gx-popup"> <b>External Link:</b><br /> You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites. <a href="#" onclick="$('.Gx-popup-component--external-link').css('display','none');return false;" class="button button-p1 Gx-popup-button-cancel"><span class="icon-right"></span> <span class="button__elipsis">...</span> Cancel</a> <a href="#" onclick="$('.Gx-popup-component--external-link').css('display','none');return true;" target="_blank" class="button button-p1 Gx-popup-button-ok"><span class="icon-right"></span> <span class="button__elipsis">...</span> Ok</a> </div> </div> <script> $(document).ready(function () { var root = new RegExp(location.host); //console.info("root: " + root); $('a').each(function () { var url = $(this).attr("href"); if (url) { //console.info("href: " + $(this).attr('href')); if (root.test(url)) { $(this).addClass('local'); //console.info("local"); } else if (url.slice(0, 1) == "/") { $(this).addClass('local'); //console.info("local"); } else if (url.slice(0, 1) == "#") { $(this).addClass('anchor'); //console.info("anchor"); } else if (url.slice(0, 7) == "mailto:") { $(this).addClass('maillink'); //console.info("maillink"); } else if (url.slice(0, 11) == "javascript:") { $(this).addClass('javascript'); //console.info("javascript"); } else { $(this).addClass('external'); if (['creditors.grunenthal.com','features.grunenthal.com','www.grunenthalhealth.com','ethicshelpline.grunenthal.com','www.grunenthalmeds.com','opioid-info.com','www.grunenthal-pro.com','www.e-g-g.info','www.changepain.com','careers.grunenthal.com','drug-safety.grunenthal.com','www.andromaco.cl','www.thalidomide-tragedy.com','www.grunenthal.de','www.grunenthal.at','www.grunenthal.ch','www.grunenthal.fr','www.grunenthal.nl','www.grunenthal.it','www.grunenthal.es','www.grunenthal.pt','www.grunenthal.co.uk','www.grunenthal.ie','www.grunenthal.cl','www.latam.grunenthal.com'].indexOf(this.host) > -1) { $(this).addClass('external--company'); } } } }); }); $(document).on('click contextmenu', 'a.external:not(.external--company)', function () { var self = $(this); var href = self.attr('href'); var selectorStart = self.hasClass('external--company') ? '.Gx-popup-component--external-company-link' : '.Gx-popup-component--external-link'; $(selectorStart).css('display', 'block'); $(selectorStart + ' a.Gx-popup-button-ok').attr('href', href); $(selectorStart + ' .Gx-popup span.external-url-placeholder').html(href); return false; }); </script> </body> </html>

CINXE.COM

Clincal trials portal | Clinical trials | R&D | Grünenthal Group.